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ABSTRACT
Genital Chlamydia trachomatis infection is a major public health concern.
Chlamydia is the most commonly reported infection in the United States and the most
common bacterial sexually transmitted infection worldwide. Unrecognized infection
endangers female reproductive health by serious complications such as Pelvic
Inflammatory Disease, ectopic pregnancy, and involuntary infertility. Widespread
Chlamydia control programs were implemented more than two decades ago to improve
women’s reproductive health but, despite initial success, the number of chlamydial
infections reported have increased.
One of the hypotheses put forth to explain increased chlamydial reporting
suggests that a long-term caveat of control initiatives is interference with the
development of natural occurring immunity as a result of mass screening and rapid
treatment. It is proposed that human cohorts are more susceptible to subsequent
chlamydiae infection and their increased susceptibility drive the current increase in
sexually transmitted chlamydiae case notifications.
In these studies we describe a comprehensive approach to assessing the role of
early anti-chlamydial intervention, an integral component of control initiatives, on the
subsequent development and severity of upper genital tract sequelae in a murine model of
recurrent chlamydiae urogenital infection. The development of an in vivo model of
urogenital Chlamydia trachomatis infection is central to defining the risk of developing
long term reproductive complications, delineating potential biomarkers for chlamydialinduced genital tract disease, interrogating host factors that may contribute to the
development of adverse complications, and anti-chlamydial vaccine development.
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CHAPTER 1.

CHLAMYDIAE

Historical Perspective
Tales as old as time . . . .
-Howard Ashman and Alan Menken
Descriptions of chlamydial disease date back to ancient Chinese and Egyptian
texts detailing trachoma, a blinding chlamydial ocular disease. In 2002 Dimitrakov
reviewed the expedition in which Ludwig Halberstaedter and Stanislaus von Prowazek
discovered the causative agent of trachoma [1]. In 1907, while on the island of Java,
Halberstaedter and von Prowazek pioneered early chlamydial etiology studies by
inoculating orangutans with material obtained from trachoma patients. They were able to
demonstrate the infectious nature of the pathogen by describing intracellular vacuoles in
Giemsa-stained epithelial cells derived from conjunctival scrapings of the infected
animals but incorrectly characterized the agent as protozoan.
In 1910, Linder reported finding the same type of intracytoplasmic inclusions in
the eyes of neonates and linked their neonatal conjunctivitis to intrapartum exposure in
women with unrecognized and untreated infection. Linder went on to speculate that the
infection was transmitted sexually after identifying inclusion bodies in the mother’s
cervical scrapings, urethral cells from the fathers, and in individuals with nongonnococcal uretheritis [2] [3] [4].
In the 1930’s Samuel Bedson and colleagues characterized the developmental
cycle of psittacosis particles, which at the time were thought to be viruses given their
dependence on eukaryotic cells for replication. In 1957, fifty years after the Java
excursion, C. trachomatis was successfully isolated and cultured in yolk sacs by Feifan
T’ang et al [5] [6]. It was not until the mid 1960’s that chlamydiae would be defined as
prokaryotic bacteria that possessed a non-infectious intracellular replication phase [7]. In
1969, Gordon et al described culturing chlamydiae in irradiated McCoy cells, a less time
consuming technique alternative to isolating chlamydiae in yolk sac that would
revolutionize diagnostic procedures for chlamydial infection [8].
Taxonomy
What is in a name?
–William Shakespeare
Chlamydiae are prokaryotic obligate intracellular bacteria that belong to the order
Chlamydiales. Under the Chlamydiale umbrella are the families Chlamydiaceae,
Parachlamydiaceae, Waddliaceae, and Simkaniaceae [9]. In 1999, it was recommended
that the Chlamydiaceae family be subdivided into two genera, Chlamydia and
Chlamydophila, based on the phylogenetic analysis of the 16s and 23s rRNA [10] but this
recommendation was riddled with inconsistencies and controversial amongst those in the
1

chlamydial field. As reviewed by Stephens and colleagues [11], the overwhelming
majority of publications (81% in the year 2006), continued to use the single genus name
Chlamydia, despite the implementation of the two genera system. To that end, nine
species are recognized in the Chlamydia genus: Chlamydia abortus, Chlamydia caviae,
Chlamydia felis, Chlamydia muridarum, Chlamydia pecorum, Chlamydia pneumoniae,
Chlamydia psittaci, Chlamydia suis, and Chlamydia trachomatis. Historically,
chlamydiae serovars were based on conventional immunoepitiope analysis by
monoclonal antibody directed against the major outer membrane protein (MOMP) [12].
Today, chlamydial classification includes genovar sequence data of ompA, the gene that
encodes MOMP [13] [14]. The ompA-based classifying system, when compared to the
conventional sera-based analysis, more accurately reflects strain virulence and genotypic
diversity on the population level [15].
Developmental Cycle
In the circle, the circle of life.
–Sir Timothy Miles Bendon Rice
Originally described in the 1930’s by Samuel Bedson et al [16], the unique
biphasic developmental cycle of chlamydiae has been extensively reviewed [17] [18] [19]
[20] [21] [22]. Two morphologically different forms characterize the chlamydial
developmental cycle, the elementary body (EB) and the reticulate body (RB). The
elementary body is the infectious form of the organism. Although small in size, about 0.2
to 0.4 microns in diameter, EBs are resistant to extracellular conditions and are able to
attach and enter susceptible host cells. Once endocytosed into the host cell, EBs
differentiate into RBs inside a membrane bound vacuole called an inclusion. Reticulate
bodies are the metabolically active and non-infectious intracellular forms of chlamydiae
which multiply via binary fusion within the inclusion. After repeated cycles of cell
division, RBs undergo a second differentiation stage resulting in infectious chlamydial
EBs. Depending on the Chlamydia species, infectious progeny exit the initially infected
cell between 30-72 hours post infection and infect neighboring host cells (Figure 1-1).
For millions of years Chlamydia species have infected eukaryotic cells and many
researchers believe that they have ensured their survival by deviating from their normal
biphasic developmental cycle. Persistence, a reversible interruption in the productive
intracellular chlamydial growth cycle by environmental factors, has been reviewed many
times over [23] [24] [25] [26] [27] and is characterized by large aberrant non-replicating
RBs which are unable to alternate between EB and RB morphological forms. In vitro
inducers of this abnormal growth state include physiological changes in the host cell,
gamma interferon treatment [28] [29] [30] [31] [32], beta lactam administration [33] [34]
[35], nutrient restriction [36] [37] [38] [39] [40], and concurrent herpes infection [41]
[42] [43]. By definition, restoration of normal chlamydiae development occurs when the
environmental stressor that induced the persistent state is removed. While the likelihood
of persistence being involved in chlamydiae-induced pathogenesis has been documented
in a variety of culture-based systems, particularly as it relates to antibiotic treatment and
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1. Attachment and
Entry

6. Release

2. Primary
Differentiation
Persistence

5. Secondary
Differentiation

3. Cell
Division

4. Genomic Replication

Figure 1-1.

Chlamydiae developmental cycle.

Note: Chlamydiae share a unique biphasic developmental cycle consisting of the
following steps: 1) Attachment and entry of the infectious Elementary Body (EB) form 2)
Primary differentiation from the infectious EB form to the metabolically active but noninfectious Reticulate Body (RB) form in a cytoplasmic vacuole called an inclusion 3)
Cell division by binary fission 4) RB genomic replication 5) Secondary differentiation
from RB to EB and 6) Cell lysis/endocytosis and release of infectious progeny.
Chlamydiae may enter an abnormal state of growth called persistence under the selective
pressure of a variety of inducers. Chlamydiae re-enter the cycle and resume normal
development when the selective inducer is removed.
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host immunological pressures, conclusive evidence of human chlamydial persistence
remains to be demonstrated.
Chlamydiae Clinical Significance
Chlamydial infection is of global importance given its broad host tropism, the
scope of its geographic distribution, and the risk of developing debilitating sequelae. Of
the nine Chlamydia species, three are known to cause a diverse spectrum of diseases in
human populations: Chlamydia pneumoniae, Chlamydia psittaci, and Chlamydia
trachomatis (Table 1-1).
Chlamydia pneumoniae
So you’re telling me that you can catch Chlamydia by just breathing? There goes the
neighborhood.
–Corey Dannard
Chlamydia pneumoniae was introduced as a novel member of the genus
Chlamydia by Grayston et al in 1989 and is commonly associated with upper respiratory
infections. C. pneumoniae causes approximately ten percent of community-acquired
pneumonia and five percent of pharyngitis, bronchitis, and sinusitis [44]. In addition,
strong associations exist between C. pneumoniae infection and atherosclerosis, a chronic
cardiovascular disease whose complications lead to half of the adult deaths in the United
States and other parts of the western world (Reviewed by Belland et al [45]). It is
important to note that the association between Chlamydia pneumoniae and
atherosclerosis is a point of debate given the failure to improve clinical outcomes with the
administration of antichlamydial antibiotics in large scale clinical trials including patients
with cardiovascular disease [46] [47] [48].
Chlamydia psittaci
You do know, of course, that zoonotic doesn’t mean the viruses came from the zoo.
–Law and Order: Criminal Intent
Chlamydia psittaci, a zoonotic pathogen whose natural reservoir is avian, is
recognized by the Centers for Disease Control and Prevention as a category B select
agent due to the ease of respiratory dissemination and associated morbidity and mortality
rates [49] [50]. As reviewed by Harkinezhad and colleagues, human C. psittaci infection
is called psittacosis and is acquired by inhalation or, to a lesser extent, ingestion of bird
excretions [51]. After inhalation, the organism infects the respiratory epithelium and
remains latent for up to three weeks void of clinical symptoms. Following the incubation
period those infected experience flu-like symptoms such as headaches, chills, fever,
cough, and in rare instances, neurological and cardiac-related complications. In extreme,
untreated cases the infection can be fatal.
4

Table 1-1.

Chlamydiae that cause human disease.

Species
C. pneumoniae

Serovar

C. psittaci

C. trachomatis

A, B, C
D,E,F,G,H,I,J,K

Acute Disease
CommunityAcquired
Pneumonia
Sinusitis
Bronchitis
Pharyngitis

Sequelae
Arthritis

Atypical Pneumonia
Renal and Hepatic
Complication

Potentially Fatal

Conjunctivitis
Cervicitis, Urethritis

Asthma
Arthrosclerosis*

Trachoma
Pelvic Inflammatory
Disease (PID)
Ectopic Pregnancy
Involuntary
Infertility
Reiter’s Syndrome
LGV
Lymphogranuloma
Fitz-Hughes-Curtis
venereum (Bubonic) Syndrome
Note: * indicates debated chlamydial-sequelae association.
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Chlamydia trachomatis
Chlamydia trachomatis is composed of four biovars, biological strains, based on
the target cells they infect and whole genome sequencing [52] [53] [54]. As implied by
the names, the ocular trachoma lineage commonly infects eye mucosa while urogenital
linages most commonly infect the genital epithelia. Lymphogranuloma venereum (LGV)
is a disseminating biovar that thrives within the lymphatic niche. Trachoma biovars are
subdivided into fifteen serovars based on ompA antigenic variation encoding the major
outer membrane protein (MOMP). Loosely, serovars A, B, Ba, and C serve as the
causative agent of Trachoma, the leading cause of infectious blindness throughout the
world. Serovars D-K are commonly associated with sexually transmitted infection. While
L1, L2, L3 are the three main LGV serovars, the newly identified L2b serotype has
emerged as the causative agent of the current European and North America epidemic
[54].
Ocular Chlamydia trachomatis
The earliest documented historical accounts of chlamydial infection detail
trachoma, a contagious disease of the conjunctiva, the outside covering of the eye, and
cornea caused by Chlamydia trachomatis. While trachoma rarely occurs in western
societies, ocular serovars of C. trachomatis are epidemic in parts of Africa, Asia, South
America, Australia, and the Middle East making it the world’s leading cause of
preventable infectious blindness.
Active infection, a self-limiting inflammation of the conjunctiva, is primarily seen
in children and is transmitted by direct contact with mucosal secretions, poor sanitation,
inanimate objects such as towels and clothing that have infected secretions on them, and
natural vectors such as flies (Reviewed by [55] [56]). Recurrent infection, which is
common in developing countries, leads to the development of scarred tissue and,
eventually, trichiasis, inversion of the eyelid. Inwardly turned eyelashes cause physical
damage to the cornea. This results in the blindness seen primarily in endemic adult
populations. The World Health Organization endeavors to eliminate trachoma by the year
2020 with the implementation of the S.A.F.E. campaign which includes surgery,
antibiotics, facial cleanliness, and environmental improvements [57] [58].
Genital Chlamydia trachomatis
Sexually transmitted diseases are hidden epidemics of tremendous health and
economic consequence in the United States…the scope, impact and consequences of
STDs are under recognized by the public and health care professionals.
–Institute of Medicine, 1997
Sexually transmitted Chlamydia trachomatis has a significant impact on human
health given its adverse effects on reproduction. The World Health Organization
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estimates that ninety million cases of chlamydial infection occur worldwide each year
and an estimated four million cases are reported annually in the United States. Many
believe these estimates are much lower than the actual incidence due to the fact that
infection is largely asymptomatic. While individuals who are infected may not experience
symptoms, it is important to note that they are still at risk of developing long term
sequelae.
In men, C. trachomatis primarily infects the urethra making it the most common
cause of non-gonococcal urethritis. In some instances, the infection spreads from the
urethra to the epididymis resulting in epididymitis, a condition primarily associated with
sexually active males under the age of thirty-five. Infection may also result in Reiter’s
Syndrome in male and female populations. Whether or not Chlamydia infection plays a
direct role in male infertility is still controversial despite the fact that chlamydial DNA
can be recovered from a substantial number of male partners in infertile couples [59] [60]
and has been recovered attached to spermatozoa from the peritoneal fluid of women with
salpingitis [61].
Genital serovars of chlamydiae are of particular importance to women due to the
irreversible reproductive sequelae that may result post infection. Infection of the cervix
can ascend causing endometritis, inflammation of the endometrium, and salpingitis,
inflammation of the fallopian tubes. Untreated C. trachomatis infection has been linked
to chronic complications such as Pelvic Inflammatory Disease (PID), involuntary
infertility and ectopic pregnancy. Moreover, chlamydial infection increases the risk of
contracting human immunodeficiency virus (HIV) and has been implicated in the
development of human papilloma virus (HPV)-induced cervical neoplasia [62] [63].
Although rare, C. trachomatis-induced salpingitis spreading beyond the upper genital
tract into the peritoneum has been documented. The resulting peritonitis and perihepatitis
is called Fitz-Hugh-Curtis Syndrome and may be accompanied by upper quadrant
abdominal pain and the development of adhesions that resemble the strings of a violin
[64] [65].
Mouse Model of Genital Infection
Life is hard for insects. And don’t think mice are having any fun either.
–Woody Allen
Humans are not the only hosts in which chlamydiae can establish an infection and
cause disease. Guinea pigs, turkeys, sheep, and higher order primates have been used to
study chlamydiae-associated disease but an extensive amount of data has been extracted
from mouse models. Mice infected with either C. muridarum or human biovars of C.
trachomatis are most frequently used as models of chlamydial genital infection due to the
ease of reproducibility afforded by inbred strains, commercial ability of reagents, and
genetically engineered animals that allow for immunological interrogation [66].
While nonhuman primate [67] [68] [69] and guinea pig [70] [71] models of
infection were established, Barron and colleagues [72] developed a novel system in
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which researchers intravaginally infected mice with Chlamydia muridarum, previously
known as C. trachomatis mouse pneumonitis strain or MoPn, in 1981. In the Barron
study, chlamydial inclusions were identified by examining Giemsa stained vaginal smear
preparations and chlamydiae-specific immunofluorescent cervical scrapings and
epithelial tissue. These findings were significant because they identified a convenient
model using a natural mouse pathogen that induced pathologies remarkable similar to
those observed in humans infected with C. trachomatis serovar D [73].
Mouse models of chlamydial infection have been used to evaluate the role a
host’s genetic background may play in chlamydiae infection resistance and Chlamydiaassociated outcomes. De la Maza and colleagues intravaginally infected mice with
varying H-2 complexes to determine its effect on chlamydial-related infertility [74]. The
H-2 complex defines the major histocompatibility complex (MHC) in mice and is
homologous to HLA in humans. Six weeks after challenge BALB/c, C57BL/6, and C3H
mice were mated with male breeders and the embryos were counted. Seventy-five
percent (N=20) of C57BL/6 mice became pregnant and had a mean of 4.5 embryos per
mouse. Forty percent (N=20) of BALB/c mice became pregnant and had a mean score of
1.5 embryos per mouse. Thirty percent (N=20) of C3H animals became pregnant and had
a mean score of 1.7 embryos per mouse. From these studies the researchers concluded
that the genetic makeup of the host modulates the degree of chlamydial-induced
infertility. In 1997, Darville et al expanded the study by comparing C3H/HeN mice with
C57BL/6 mice using varying strains of Chlamydia [75]. When intravaginally infected
with C. trachomatis, serovar E or C. muridarum, C3H mice had an increased incidence of
hydrosalpinx, increased chlamydial shedding, and prolonged infection course when
compared to C57BL/6 animals. This suggested that genetic factors played a role in
chlamydial resistance and that the murine model could be used to understand the
mechanisms responsible for resistance variability in the human population.
Advances in human genetics, such as the human genome project, have
revolutionized our understanding of the host’s role in human health and disease by
allowing for inter- and intra-species genetic comparisons [76] [77]. Indeed, whole
genome association studies would allow researchers to interrogate genes and their
associated disease phenotypes relatively quickly when compared to the previous method
of “knocking out” genes in in vivo models and looking for changes in the initially
observed response. As one would expect, identifying conserved genetic sequences across
diverse species would require vast amounts of genetic information. This requirement
grants the mouse model a significant advantage over other animal models given the fact
that genetic sequences and many gene function relationships have been identified and are
readily available using informatics tools like the Mouse Genome Database
(http://www.informatics.jax.org/).
Although chlamydial comparative studies are still in their infancy, highthroughput genomic analyses have the potential to transform how we currently identify
and therapeutically treat those infected. As proof of principle, Miyairi and colleagues
recently sought to predict outcomes of systemic chlamydial infection using recombinant
inbred mice (BXD) and computational modeling [78]. Infection of parental strains,
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C57BL/6 and DBA/2J, an extensive panel of B (C57BL/6) x D (DBA/2J) mice, in
conjunction with gene mapping and computational Bayesian network modeling were
used to define underlying pathways contributing to variations in disease severity. The
researchers validated predictions that Ctrq3 or polymorphisms in immunological relevant
GTPases conferred resistance in B6 dominant genetic backgrounds, whereas,
susceptibility was heightened in D2 dominant backgrounds as a function of neutrophilic
influx modulation. While there are no homologs of interferon-inducible p47 GTPases in
humans, Miyairi’s findings implicate neutrophils as a tentative therapeutic target, validate
computational chlamydiae-related modeling as a way of predicting disease outcomes, and
highlight recombinant inbred strains as a way of elucidating previously unknown hostderived pathways contributing to disease.
Murine Genital Tract Pathology
C. muridarum, although originally isolated from the murine respiratory tract [79]
[80], closely mimicked human sexually transmitted chlamydiae disease when used to
infect the genital tracts of mice. In 1983, Swenson and colleagues reported Chlamydiainduced genital pathology mirrored that seen in human populations [81]. In these
experiments mice were inoculated with C. muridarum in the ovarian bursa, a thin
membrane that encapsulates the ovary and separates it from the interperitoneal cavity.
Hydrosalpinx, blockage of the fallopian tube(s) with serous fluid, was observed in mice
between 25-30 days post infection. Salpingitis and hydrosalpinx formation have been
linked to involuntary infertility in human female populations by irreversible scarring in
the reproductive system and similar outcomes were demonstrated in the model. Although
the natural route of infection was not used in this study, it validated that the mouse model
could be used to explore mechanisms associated with the development and severity of
chlamydiae-induced upper tract complications. Since, several studies, including those
outlined in this body of work, have demonstrated vaginal inoculation of the mouse results
in reproducible upper genital tract pathology.
Murine Model Limitations
Although the murine model has been advantageous, there are some caveats. For
instance, there is great variability in chlamydiae strains, innoculum doses used, and the
inbred strain used. The efficiency of infection using human strains of C. trachomatis is
significantly lessened when compared to the strain isolated from the murine respiratory
tract, C. muridarum [82]. As a result, investigators commonly use higher doses of
Chlamydia trachomatis to establish murine infections. Inoculating doses have also been a
point of debate in the chlamydial field. In 2004, Maxion and colleagues evaluated
differences in BALB/c cell infiltration and pathology formation as a result of innoculum
doses ranging from 104 to 107 inclusion-forming units (IFUs). They found that dose
variation altered immune cell representation in the genital tract noting increases in PMN
and DC infiltrates in the lower genital tract as chlamydial dose increased [83]. Carey et al
investigated the effects of inoculum dose on pathology development in BALB/c female
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mice [84]. They concluded higher doses of Chlamydia muridarum lead to greater oviduct
infection.
Lastly, and perhaps the most relevant argument, is that C. trachomatis is
transmitted by oral, vaginal, and anal sexual contact with an infected individual. The
likelihood of large amounts of infectious organisms being transmitted by the routes
mentioned is low. In support of this argument, the infectious chlamydial load in humans
is low with a median IFU of 72 from male-derived urethral swabs and 450 IFU from
cervical swabs taken from women [85]. Collectively, these studies underscore the need to
standardize infection parameters in chlamydial models across the board to reflect the
likely transmission inoculums seen in human scenarios of infection.
Another caveat of the mouse model is the five day estrous cycle. The frequency of
epithelial uterine sloughing proved to be a problem in establishing chlamydial infection
in mice because the target population (epithelial cells) was turning over prior to the
completion of the chlamydial developmental cycle. Tuffery et al performed experiments
that showed the female genital tract epithelium could be stabilized by subcutaneously
injecting progesterone one to two weeks prior to intravaginal infection (Tuffrey, and
Taylor-Robinson, 1981). Hormone treatment stabilized murine menses and enhanced
chlamydiae genital infection by preventing the normal renewal of genital epithelium. As
a result, the mouse model can be used to study the natural course of infection and
chlamydiae-induced pathology with increased reproducibility. Currently, the use of
progesterone in animal models is debated because sex hormones have been shown to
affect susceptibility to a number of sexually transmitted infections in human and animal
studies [86] [87] [88].
Another concern is the availability of a persistent murine model. In human
female populations, persistent infections defined by chronic asymptomatic chlamydial
genital tract infections, may give way to the development of reproductive complications
such as PID, chronic abdominal pain, and tubal infertility. As mentioned previously, in
vitro persistent states have been induced by environmental stresses such as the interferon
gamma inducible tryptophan decyclizing enzyme 2, 3-indoleamine dioxygenase, iron
depletion, and by treatment with penicillin. In efforts to reproduce persistence in vivo,
Ramsey et al used iNOS knockout mice [89]. When NOS2-/- mice were infected with C.
muridarum, they exhibited higher rates of upper genital tract sequelae but culture-based
resolution was comparable to that observed in wild-type mice. In 1997, Cotter et al
intravaginally infected wild-type immunocompetent mice and were able to reactivate
chlamydiae shedding after initial clearance, evidenced by the inability to recover viable
organisms from the vaginal vault, with the immunosuppressive drug cyclophosphamide
[90]. While these studies illustrate persistence in the mouse, the mouse model may not
be a useful tool for exploring mechanisms of persistent infection because it difficult to get
reactivation. Further investigation for a suitable animal model is warranted given the lack
of conclusive evidence for persistent infection in the human population.
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Immunological Response to Genital Infection
Before discussing the host immune response to sexually transmitted chlamydial
infection, it is important to note key distinctions of the female genital mucosa when
compared to other mucosal sites of the body. The reproductive environment is unique in
that it must exhibit a certain level of tolerance for commensal flora that colonize the
lower genital tract and withstand the presence of an immunologically foreign fetus in the
uterus during pregnancy, all the while maintaining its ability to mount a response to
pathogenic organisms. In addition, the genital environment differs from other mucosal
sites like the proximal intestinal system in that many of its effector functions, including
immunological properties, are hormonally regulated [91]. These distinctions and the lack
of local concentrations of lymphoid tissue such as the gut-associated lymphoid tissue
(GALT) component Peyer’s Patches in the intestine or bronchular-associated lymphoid
tissue (BALT) in the lung contribute to the complexity of chlamydiae infection in the
genital tract.
Intracellular Immune Response Overview
After “self verses non-self” discrimination, the host orchestrates appropriate
immunological responses based on the niche in which pathogens thrive [92]. Bacteria
such as Mycobacterium tuberculosis[93] [94], species associated with the genus
Rickettsia [95] [96], chlamydial species [82] [97] [98] [99] [100] [101], and viruses like
HIV [102] [103] and influenza [104] are hallmark intracellular pathogens that require
specialized approaches to achieve clearance. Antigen-presenting cells (APCs) and T-cells
are crucial to intracellular pathogen elimination. For instance, pattern recognition
receptors (PRRs) associated with APCs like dendritic cells or macrophages recognize
pathogen-associated molecular patterns (PAMPs) which, in turn, initiate antimicrobial
compounds such as interferon-gamma, tumor necrosis factor-alpha, and interleukin-two
[105]. These cytokines assist in the activation of other APCs and push naïve T-cells
(Th0) toward an appropriate TH1 pathogen-specific linage. This cascade culminates in Bcell activation and the development of plasma cells, antibody-producing B-cells that
ready the host for subsequent encounters.
Chlamydia Innate Response
Induction of the innate immune response is central to mounting an effective attack
against chlmaydial genital pathogens. The process begins with the recognition of
pathogen associated molecular patterns (PAMPS) by Pattern Recognition Receptors
(PRRs) of Antigen Presenting Cells (APCs) or host cell membranes. Various chlamydiae
components or the entire organism may serve as ligands for toll-like receptors (TLRs), a
membrane bound family of PRRs. For example, chlamydiae-derived lipopeptide was
shown to stimulate TLRs 2, 1, and 6 in macrophages [106]. Although less stimulatory
than E. coli lipopolysaccride (LPS), chlamydial LPS may serve as a ligand for TLR4
[107] and to a lesser extent TLR2 [108]. Moreover, whole organism was used to
determine differences in chlamydiae-induced oviduct pathology after discriminatory
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stimulation of TLRs 2 and 4 [109]. Stimulation of TLRs give way to activation of the
NF-K B pathway which, in turn, results in production of pro-inflammatory cytokines and
chemokines.
Almost immediately after infection, a cascade of proinflammatory cytokines are
secreted by the target epithelium. This was first reported by Rasmussen and colleagues in
1997 [110]. Using the in vitro HeLa 229 epithelial cell line, these studies showed that
interleukin-8, growth-related oncogene- alpha (GRO-alpha), neutrophil-derived
granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-6, and
interleukin-1alpha were secreted following infection. Experiments using mouse derived
oviduct epithelial cells performed by Johnson et al showed that proinflammatory
cytokines and chemokines like tumor necrosis factor alpha, GM-CSF, interleukin-6, MIP2, KC, MCP-1 and MCP-5 were produced following C. muridarum infection [111]. The
secretion of these effector molecules lead to the massive influx of innate immune cells.
Darville and colleagues, by flow cytometry, and Morrison and Morrison, by in situ
immmunohistochemistry, characterized the primary infiltrate and found that monocytes,
natural killer cells, and neutrophils were prevalent in these cell populations [75] [112].
The newly recruited cells expanded the repertoire of effector molecules being produced
and, depending on the cytokines and chemokines released, recruited pathogen-specific
lymphocytes to the site of infection.
Chlamydia Adaptive Response
Effective host responses require the induction of, both, the innate and acquired
arms of the immune system. Indeed, resident and recruited innate immune cells such as
neutrophils and professional antigen presenting cells such as macrophages and dendritic
cells begin producing tumor necrosis factor-alpha, interleukin-12, and interferon-gamma.
This stimulates naïve T cells toward CD4 T-helper 1 lineages which are necessary for
chlamydial clearance in the genital tract. Studies in interferon gamma [113] and
interferon gamma receptor knockout mice [114] illustrate a prominent role for the
cytokine in the resolution of primary chlamydial infection. Rank and colleagues first
demonstrated an important role for CD4 T cells in the genital tract by vaginally infecting
athymic nude mice [115]. Nude animals had an active infection evidenced by chlamydial
shedding for more than 200 days post infection, whereas animals with intact T cell
populations resolved infection within 21 days. Landers et al reinforced this finding in
1991 when they used CD4 antigen specific anti-L2T4 antibodies to deplete CD4 in mice
vaginally infected with C. muridarum [116]. These depletion studies resulted in
increased vaginally shedding of Chlamydia and an increased number of organisms
recovered from the oviduct. Su et al later transferred CD4 and CD8-enriched spleen cells
from immune mice to naïve mice and found that adoptive transfer of CD4 lymphocytes
conferred immunity in C. muridarum genital tract infection [117]. Kelly and colleagues
published work illustrating that CD4+ cells were abundantly recruited to the genital tract
following intravaginal infection due to interaction between CD4+ cell home receptor
alpha-4-beta-7 and adhension molecules, ICAM-1, VCAM-1, and MadCAM-1 [118]
[119]. Most recently, Gondek and colleagues reported that CD4+ T cells were necessary
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and sufficient to clear genital tract infection [120]. Using transcervical inoculation, a
method that directly infects the uterine lining of mice, the researchers demonstrated C.
trachomatis, LGV and C. muridarum infected mice are protected from infection and
reinfection when treated with pathogen-specific CD4+ lymphocytes. Furthermore, when
animals were treated with anti-CD4 antibody, Chlamydia 16S DNA levels where
comparable to those observed in naïve mice. Collectively, these studies demonstrate the
importance of T helper 1 type cytokines and CD4 T cells in the resolution and protection
of chlamydial-induced genital infection.
The humoral response has also been implicated in chlamydial immunity. Plasma
cells, commonly known as antibody producing B cells, are thought to play a leading role
in protecting against reinfection, while playing a secondary role to CD4-mediated
resolution of primary infection [99]. One mechanism by which B cells may control
subsequent infection is by antibody driven neutralization, which is plausible given the
biphasic developmental cycle of chlamydiae. Data from Peeling et al using serum from
guinea pigs to neutralize C. trachomatis with UM-4, a strain specific monoclonal
antibody in an in vitro neutralization assay support this theory [121]. Furthermore,
Morrison and colleagues showed that B-cell deficient mice, when depleted of CD4+ T
cells during secondary infection, where unable to clear infection [98] [99]. Although the
experiments by Morrison et al did not rule out the feasibility of direct neutralization, they
implicated a more collaborative mechanism between CD4 lymphocytes and plasma cells,
perhaps by the enhancement of antigen presentation during recurrent infection episodes.
Although the exact mechanism remains unclear, antibody, particularly IgG given it is the
predominant antibody produced in the genital mucosa, is thought to play a collaborative
role in chlamydial immunity.
Vaccination
The prevention of disease today is one of the most important factors in the line of human
endeavor.
–Charles H. Mayo, M.D.
The immune response is the host’s natural defense mechanism to foreign antigens
but the system can be manipulated to respond to foreign antigens quicker and more
efficiently than if it were the first encounter. The previously mentioned form of
manipulation serves as the basis for vaccination or, what some refer to as immunization.
Although current anti-chlamydial therapies effectively clear the organism from
the lower genital tract, they do not address the potential consequences of reinfection.
Batteiger and colleagues reported that almost one third of previously infected individuals
are reinfected with the same serovar due to sexual interaction with the same sexual
partner [122], potentially increasing the likelihood of irreversible tissue damage. One
way of addressing reoccurring infection is through the development of an effective and,
most importantly, safe vaccine.
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Perhaps the most well-known C. trachomatis vaccination studies were the
trachoma human trials performed in the 1960’s [123] [124]. During these trials children
were intramuscularly vaccinated with formalin-fixed whole organisms and traced for
three years. Unfortunately, a portion of those immunized developed severe disease upon
exposure to chlamydiae while others developed partial, serovar-specific immunity when
compared to unvaccinated controls. Since then, vaccination studies have been exclusively
performed in animal models and frequently exploit components of chlamydiae for
vaccination.
First purified by Caldwell and colleagues [125], the major outer membrane
protein (MOMP) has been the focal point of chlamydiae subunit vaccination studies for
the past thirty years. Recently reviewed by Farris and Morrison, native or recombinant
protein, DNA, plasmid, and outer membrane complexed MOMP have been the most
frequently studied MOMP-derived antigens [126]. At best, these studies have only
elicited partial immunity by either failing to reduce bacterial burden, failing to protect
animals from reinfection, and/or failing to protect against sequelae formation.
Interestingly, recombinant vault nanoparticle delivery of MOMP immunogens has
renewed hope in MOMP’s potential as an effective vaccine candidate. Intranasal
immunization with rMOMP nanoparticles results in a T-helper 1 driven immune response
and significantly reduces chlamydial vaginal shedding when compared to animals
immunized with live C. muridarum [127].
Additional antigens have been identified based, mainly, on human seroactivity.
Some of these include chlamydial protease-like activity factor (CPAF), other outer
membrane proteins such as OmcB and Pmps, porin protein B (PorB), and the type III
secretion protein, Tarp. Of the previously mentioned chlamydial components, CPAF was
thought to have the most promise. Intranasal immunization with recombinant CPAF
(rCPAF) plus interleukin-12 reduced bacterial shedding and sequelae formation in
BALB/c intravaginally challenged with C. muridarum [128]. In addition, rCPAF and
Cpg-1826 was used to intranasally immunize BALB/c mice prior to multiple rounds of C.
muridarum intravaginal challenge [129]. rCPAF plus CpG vaccination resulted in a
significantly greater number of pregnancies when compared to mock immunized controls
indicating protection post primary and secondary exposures to genital chlamydial
infection. In 2012, Chen et al called into question the entire body of work done using
CPAF and its proposed substrates after reporting CPAF lost its ability to cleave or
degrade 11 of the 16 previously reported host proteins when a CPAF- specific inhibitor
was used prior to cell lysis [130]. These results suggest that the proteolysis activity
observed in all previous CPAF studies was likely due to the way in which the
preparations were prepared and discredit, at least for now, the idea that CPAF protease
activity is a virulence factor important in chlamydial pathogenesis.
Control Measures
Chlamydia trachomatis infection is the most commonly reported sexually
transmitted disease in the United States and a significant threat to public health worldwide. Chlamydia control programs were implemented to alleviate the public health
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burden of chlamydial infection by improving detection mechanisms, shortening the
duration of infection, and tracking source-associated sexual networks [131]. These
programs ushered in an initial lag phase denoted by a decline in chlamydial cases.
However, over the last two decades, case notifications of Chlamydia-associated infection
have steadily increased and, in many countries, exceed rates recorded prior to the
implementation of intervention strategies [132] [133] [134]. Norway, Finland, Sweden,
and Canada have documented similar trends with an initial decline following the
introduction of Chlamydia control programs [132] [135] [136] [137]. In recent years,
these countries have witnessed chlamydial rates exceeding those recorded prior to the
establishment of surveillance systems. Given the magnitude and scope of current
epidemiological trends, researchers and policy makers alike are interested in pinpointing
the causal agent(s) for increased chlamydial case notifications.
Sexually Transmitted Chlamydia Epidemiology
The insidious nature of Chlamydia trachomatis infection has made it the world’s
most common cause of curable sexually transmitted disease. In 2010, over a million cases
(1,307,893) of chlamydial genital tract infection were reported to the Centers for Disease
Control and Prevention from fifty states and the District of Columbia [63]. This was the
largest number of cases reported to the CDC for any reportable condition with a case rate
of 426.0 per 100,000 people, representing a 5.1% increase in reported cases over the
previous year. Although these rates are staggering, the actual number is more than likely
higher than that reported seeing as many cases remain undiagnosed.
Gender disparities have consistently been reported among individuals infected
with sexually transmitted C. trachomatis. According to the National Sexually Transmitted
Disease Surveillance Report 2010, women bear a heavier Chlamydia burden than men
with reported rates two and half times more than their male counterparts despite the fact
that Quinn and colleagues reported a nearly identical frequency of transmission among
494 male and female sexually transmitted disease clinic patients [138]. This discrepancy
may be attributed to the fact that women are more likely than men to be screened for
chlamydial infection [139]. However, the switch from urethral swabbing to urine-based
non-invasive nucleic acid amplification testing as the main detection method may result
in more men opting to get tested [140] [141]. This is supported, at least in part, by the
36% increase in chlamydiae case notification since the year 2006. A 19.5% increase was
observed in the female population between 2006 and 2010, indicating the increase in
male reporting was not solely because of an increase in population-based chlamydiae
prevalence [63].
Age has been implicated as a risk factor for urogenital chlamydial infection [142]
[143] [144] [145] [146] [147] [148]. The highest notification rates correspond to sexually
active female adolescents between the ages of 15-19. The second highest rate among
females is young adults between the ages of 20-24. Age-specific rates among males are
higher among 20-24 year olds with 1,187 cases per 100,000 people reported in the year
2010. These numbers are particularly troubling considering chronic chlamydial
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complications have been linked to infertility in both genders and the age groups greatest
affected represent peak reproductive years [63].
Significant ethnic and racial disparities exist among reported sexually transmitted
infections, specifically Chlamydia cases. For instance, African-Americans only represent
14% of the national demographic, but they account for approximately half of all reported
syphilis and chlamydiae cases and 75% of all reported gonorrhea infections [63]. With an
incidence rate 1,167.5 per 100,000 persons, African-American chlamydial rates are eight
times higher than white Americans. American Indian/Alaska Natives chlamydial rates
are 4.3 times higher than white Americans while Hispanic American chlamydial rates are
2.7 times greater than those reported among Caucasian-Americans. While it would be
easy for researchers and epidemiologists to dismiss these health inequalities based on the
idea that these communities are more susceptible to infection and/or are more likely to
participate in risky behaviors, the reasons are more complex [149]. While individual
behaviors can influence health, surveillance trends are, in large part, influenced by
cultural, economical, environmental, educational, and social factors [150] [151] [152].
For instance, in a study conducted by Kaplan and colleagues in 77 different Chicago
communities, sexually transmitted infections were higher in neighborhoods that had high
poverty rates, high unemployment rates, and a low percentage of high school graduates
[153]. In a cross-sectional analysis of over 12,000 young adults, Nguyen et al concluded
that geographical location and economic status were factors associated with chlamydial
reporting with study participants living in the southern region and no functional income
being more likely to report chlamydiae infection [154]. While the studies citied highlight
findings seen in relatively small participant groups, they are representative of health
determinants influencing national surveillance profiles.
Hypotheses for Rebounding Chlamydia Rates
Seven hypotheses were put forth to explain this phenomena and were published
by Rekart and Brunham [133] and are adapted in Table 1-2. Hypotheses one through
four relate to the use of nucleic acid amplification testing for detecting genital infection
with chlamydiae. Hypothesis one speaks to an increased probability of “false positive”
tests because of a loss of specificity in detection methods. Watson and colleagues
performed a meta-analysis including the following diagnostic methods for urogenital
chlamydia: nucleic acid amplification testing (NAAT), gene probe, enzyme immunoassay
(EIA), direct immunofluorescence (DFA), and cell culture [141]. The study concluded
that NAAT testing was the best option for massive screening programs because the
results were comparable to those observed using the “gold standard”, cell culture, and
urine samples did not constitute a gender bias. Men and women would be willing to
undergo screening using this non-invasive technique.
Hypotheses two through four argue increased sensitivity, improved screening
amongst high-risk populations, and greater screening among the male population are the
basis for surveillance data trends. In 2006, Burckhardt et al assessed the impact of
changing from culture-based chlamydial detection to nucleic acid amplification testing in
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Table 1-2.
Hypothesis
Number
H1

Increased chlamydial rate hypotheses.
Hypothesis Description
False positive increase due to lower specificity of NAAT methods
compared to culture methods

H2

Increase in case detection due to increased sensitivity of NAAT testing
compared to non-NAAT testing

H3

Higher testing rates among men due to non-invasive NAT urine-based
testing

H4

Targeted screening of high-risk populations and NAAT self-collected
sampling among female population(s)

H5

Development of antibiotic resistance

H6

Increase in unsafe sexual behaviors

H7

Chlamydial arrested immunity
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a genitourinary medicine clinic cohort [155]. Although an initial increase in positive
testing occurred in the two and half years immediately following the implementation of
NAAT testing, positive test percentages returned to those observed prior to the detection
method change. The researchers concluded that the upturn of chlamydial incidence was
not exclusively due to the improvement of detection methods.
Hypothesis five suggests antimicrobial resistance is responsible for the
rebounding rates. Indeed, antibiotic resistance is a serious issue, particularly for
individuals infected with syphilis and/or gonorrhea [156] [157] [133] [158], two major
sexually transmitted infections. Although tetracycline resistance has been documented in
chlamydiae serovars that infect livestock [159], resistance among human isolates are
rarely observed.
Hypothesis six implicates the safe sex practices, or lack thereof, as a potential
cause. Undoubtedly, the behavioral choices made by individuals influence populationbased surveillance data. Perhaps the ideal example is that of HIV/AIDS. After the initial
recognition of HIV in the early 1980’s, huge awareness campaigns were implemented
that led to a decline in STI transmission across the board [160] [161]. After effective
treatment was introduced and the general population no longer viewed HIV/AIDS as a
“death sentence”, STI incidence rates rebounded. This demonstrates that effect of human
behavior on modulating infection cases and confirms the likelihood of current trends
being a result of several factors.
The final hypothesis is the arrested immunity hypothesis. Although it is important
to remember that none of the previously mentioned postulates are likely to be mutually
exclusive, the arrested immunity hypothesis is the cornerstone of my dissertation research
and the primary theme hereafter.
Arrested Immunity Hypothesis
The arrested immunity hypothesis asserts that prompt treatment of genital tract
infection is coupled with a reduction in naturally acquired immunity, resulting in
increased incidence and prevalence of chlamydial infection [132]. Interference with the
development of host immunity to chlamydiae genital infection has been shown using the
urogenital murine model by the Caldwell research group [162]. Su and colleagues treated
C57BL/10 female mice with doxycycline at different timepoints postinfection. No IgG
antibody was detected in sera from animals that received treatment at day zero, the onset
of infection. This demonstrated the effects of early treatment on the development of antichlamydial immune responses.
Brunham et al applied the Cox proportional hazards model to evaluate the effects
of antibiotic treatment on the development of population-based immunity [163]. The Cox
model is a statistical survival model developed by Sir David R. Cox that relates the time
between an “event” occurring to one or more covariates that make also occur within that
time frame. The Brunham model is hinged on findings by Molano and colleagues [164]
suggesting immunity in human populations may take years to develop. These findings,
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when considered with the early treatment component of control programs, suggest that
human hosts don’t develop an adequate immunological response to chlamydiae due to the
truncated exposure time with chlamydial antigen(s) in the genital tract. Using the Cox
model, Brunham’s groups concluded that early treatment renders the general population
more susceptible to reinfection.
Dissertation Rationale
Despite the implementation of wide-spread control initiatives, sexually
transmitted Chlamydia rates continue to rise and are coupled with a decline in
chlamydiae-associated chronic complications such as PID, ectopic pregnancy, and
involuntary infertility [131]. Several rebounding hypotheses have been put forth to
explain current surveillance trends and, optimally, humans studies would provide the
most insight as to why intensive screening and treatment strategies are, seemingly,
ineffective. For obvious reasons, these studies are impractical given the ethical concerns
surrounding trials undertaken with the potential of chlamydial-induced upper genital tract
complications. Taking into account current therapeutic intervention, immune arrest and
infection history, we used the chlamydiae urogenital mouse model to determine the
effects of antibiotic treatment on duration of infection, immunological parameters and,
most importantly, chlamydial-induced upper tract complications in primary and
reoccurring cycles of infection. Moreover, we documented the effects of host factors,
such as age and genetic make-up, and immunization on the development of severe
chlamydial-induced genital tract disease.
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CHAPTER 2.

ARRESTED IMMUNITY: IMPACT OF EARLY TREATMENT
ON UPPER GENITAL TRACT SEQUELAE
Introduction

Sexually transmitted Chlamydia trachomatis is the most commonly reported
notifiable infection in the United States [147]. Although up to 75% of women and 50% of
men with lower tract chlamydial infections are asymptomatic [165] [166] [167], the
potential to develop genital tract sequelae remains unchanged when compared to
individuals that experience symptoms such as postcoital bleeding, fever, abdominal pain,
and mucopurulent vaginal discharge [168]. This is of particular concern given the
reported rate of chlamydial infection among women is over two and half times greater
than the reported rates for men [147] and C. trachomatis infection can ascend into the
female upper genital tract causing long term reproductive complications such as ectopic
pregnancy, involuntary infertility, miscarriage, and increased risk of coinfection and
transmission of other pathogenic agents [169] [170] [171] [172]. As a result, in the
absence of a protective chlamydial vaccine, Chlamydia prevention efforts mainly focus
on increasing the rate of screening and treating infected individuals [134] [170] [173].
While current antibiotic regimens are highly effective in clearing the organism
during uncomplicated lower genital tract infection [174] [175], it has been reported that
doxycycline treatment prevents the development of host immune responses in a murine
model of chlamydial genital infection [162]. Furthermore, Brunham and Rekart
hypothesized that populations were susceptible to reinfection due to a shortened duration
of C. trachomatis encounters which may limit natural immunity [132] [133]. Indeed,
repeated chlamydial exposure has been identified as a risk factor for worse disease in
animal and human studies when compared to reference groups that have only been
exposed once or are considered low-risk sexually transmitted disease populations [176]
[177] [178]. Among a high- risk population of sex workers, reoccurring C. trachomatis
infection was associated with Pelvic Inflammatory Disease [179]. Similarly, in a
retrospective study of 11,000 Wisconsin women, ≥3 positive chlamydial tests increased
the chances of Pelvic Inflammatory Disease diagnosis by a factor of six [177]. Although
these studies indicate an increased risk for severe disease following multiple positive
Chlamydia tests, they fail to distinguish between prolonged exposure and reinfection, or
the role antibiotic intervention played, if any, in the development of disease. This is
further complicated by the initial decline in reported chlamydial infection rates following
the introduction of screening and treatment control programs which have since rebounded
to levels comparable or exceeding those observed prior to the implementation of
intervention strategies.
In this study, we sought to determine if data derived from population surveillance,
human studies, and in vivo experiments could be recapitulated using the urogenital mouse
model as a framework to determine how treatment at various time-points throughout the
course of an active primary infection affects disease outcomes during repeated infection
cycles.
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Materials and Methods
Mice
7 to 8 week old C57BL/6J mice were purchased from the Jackson Laboratory
(Bar Harbor, ME) and maintained at our facility, which is fully accredited by the
Association for Accreditation and Assessment of Laboratory Animal Care International.
The Animal Care and Use Committee at the University of Tennessee Health Science
Center (Memphis, TN) approved all animal studies.
Chlamydia Strain and Titration
The Chlamydia muridarum Weiss strain was propagated in HeLa 229 cells and
stored at -80oC. Chlamydial titer was evaluated by infecting HeLa 229 cells and counting
Inclusion Forming Units (IFUs) by fluorescence microscopy as previously described
[113].
Mouse Infection
Mice were subcutaneously treated with 2.5 mg of medroxyprogesterone acetate
(Sicor or Depo-Provera, Pfizer, New York, NY) in 0.1 mL of PBS at fourteen and seven
days prior to vaginal infection. Mice were infected by vaginal inoculation with 2 x 103
IFU of C. muridarum in 10 uL of sucrose phosphate glutamic acid (SPG) buffer. For
rechallenge experiments, mice were treated with progesterone and vaginally challenged,
as previously described, fifty-six days post primary infection unless otherwise specified.
Antibiotic Treatment
Mice were treated daily with 0.3 mg of doxycycline hyclate (APP
Pharmaceuticals, Schaumburg, Il) diluted in distilled, endotoxin-free water (HyClone,
Logan, Ut) by interperitoneal injection during the primary infection course only. All
treatment groups received antibiotic for fourteen days consecutively except for
uninfected, negative control mice treated with progesterone. Treatment groups included
treatment from 0-14 d, 14-28 d, 28-42 d, 35-49 d, and Untreated-(UN).
Bacterial Shedding
Vaginal swabs were taken on interval days throughout infection and collected in
2-mL microcentrifuge tubes that contained 0.5 mL of SPG (with three 4mm diameter
round glass beads) and stored at -80oC. Swab samples were thawed and vortexed.
Infectivity was quantified by inoculating Hela 229 monolayers seeded in 48-well plates
with swab supernatant fluid. After 44 h incubation at 37oC in an atmosphere of 5% CO2,
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plates were washed with PBS-Azide and methanol fixed. Chlamydial inclusions were
visualized and counted by fluorescence microscopy.
Fluorescence-Linked Immunosorbent Assay (FLISA) Antibody Analysis
For total immunoglobulin G (IgG) and IgG isotype studies, HeLa 229 cells were
seeded in 48-well plates (CoStar, Corning, NY) at a cell number of 105 cells/well
overnight. HeLa 229 monolayers were infected with C. muridarum at a multiplicity of
infection (MOI) of two for 2 hours with consistent rocking at 37oC. The innoculum was
immediately aspirated and plates were incubated in Dulbecco’s Modified Eagle Medium
(DMEM) (Life Technologies, Carlsbad, California) complete containing 2ug/mL of
cycloheximide for 36 hours at 37oC in an atmosphere of 5% CO2. Following incubation,
plates were washed 3 times with PBS-Azide and fixed with 500 uL of methanol per well
for 10 minutes. After fixation, plates were washed 3 times with PBS-Azide and incubated
at 37oC with a 1:500 dilution of murine sera, pooled based on antibiotic treatment group,
in PBS/0.1% grade IV ovalbumin/0.05% Tween 20. After incubation, plates were washed
3 times and incubated with FitC-conjugated rat anti-mouse IgG, IgG1, IgG2a, IgG2b
(Southern Biotech, Birmingham, AL), FitC-conjugated goat anti-mouse IgG2c, or Alexa
Fluor ® 488 -conjugated goat anti-mouse IgG3 (Invitrogen by Life Technologies,
Carlsbad, California) for thirty minutes. Plates were washed 3 times with PBS-Azide and
fluorescence intensity was immediately read as fluorescent light units (FLUs) at
sensitivity 70 using a Biotex Synergy 2 Microplate Reader. Results represent the mean of
triplicate values for each pooled sample group while the solid horizontal bar denotes
background intensity as measured by normal sera from uninfected untreated animals.
Pathology
Immediately following sacrifice, individual mice were grossly examined for
genital tract pathology abnormalities and photographs were taken. The uterine horns and
oviducts were collectively and separately scored based on dilation and visual
inflammation (reddening and blockage) of the aseptically removed urogenital tissue.
Scoring for dilation of uterine horn and oviduct tissues was as follows: 0, normal/no
significant dilation; 1, mild dilation of a single cross-section; 2, one to three dilated crosssections; 3, more than three dilated cross-sections; 4, confluent dilation. Excised tissues
were methanol fixed and paraffin-embedded. Longitudinal sections were later stained
with one of the following: hematoxylin and eosin (H&E), NIMP-R14 (neutrophil
identifying marker), CD68 (macrophage identifying marker), CD4 (T-cell identifying
marker), and Toluidine Blue (mast cell identifying stain).
Organ-Total Body Weight Ratio Analysis
Mice were individually weighed to obtain the total body weight in grams.
Immediately following sacrifice, the genital tract was aseptically removed and weighed in
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milligrams. Organ-total body weights were expressed as a function of organ weight
divided by total body weight to generate weight ratios. Weight ratios for each animal
were averaged by corresponding antibiotic treatment group.
Statistical Analysis
Statistical significance of differences between treatment groups was analyzed
with GraphPad Prsm 4 software (La Jolla, CA) using one-way analysis of variance
(ANOVA) with post hoc Tukey testing comparing all possible pairs of means unless
otherwise noted. The strength of linear correlations was determined using Pearson
product moment correlation coefficient unless otherwise noted. All analyses were
performed using two-tailed testing at a 95% confidence interval of difference.
Results
Kinetics of Genital Tract Infection in Antibiotic-Treated Mice
To evaluate the effect of antibiotic treatment on the duration of chlamydial
infection, cervicovaginal swabs were collected throughout the primary course of
infection. Progesterone treated mice were vaginally infected with 2 x 103 IFU
chlamydiae, treated with doxycycline and swabbed as described in Materials and
Methods. Mice infected but not treated displayed kinetics of an active infection shedding
3-5 log10 of viable organisms within the first 3 weeks (Figure 2-1). These untreated
animals were culture negative, indicating a natural resolution of lower genital tract
infection, by approximately week four. We were unable to recover infectious organisms
at day four after inoculation in early treated animals, the earliest time point analyzed.
This suggests that antibiotic treatment prevented intravaginal chlamydial colonization,
negating the establishment of an active urogenital tract infection. Mice that started
treatment at an intermediate time point (14-28 d) exhibited a rapid reduction in
recoverable organisms after the onset of treatment, whereas, groups treated late during
the infection cycle (treatment initiation at day 28 or 35) paralleled untreated clearance
rates.
Immune Arrest and Pathology Following Primary Infection of Antibiotic-Treated
Mice
Antibiotic treatment has been shown to prevent the onset of host immune
responses and the development of upper tract pathology post primary infection [162]
[180]. To assess whether an immunological response had occurred we measured systemic
chlamydial specific IgG antibody titers post primary infection by FLISA in addition to
scoring the severity of disease. As hypothesized, pathology following primary challenge
was significantly reduced in early treatment groups when compared to later treatment
groups or untreated controls (Figure 2-2). Animals that began treatment at 14 days post
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Figure 2-1.

Shedding of viable C. muridarum following intravaginal challenge.

Note: Solid lines represent various antibiotic treatment groups. Blue: Untreated control,
Red: (0-14 d), Green: (14-28 d), Purple: (28-42 d), Aqua: (35-49 d). Symbols represent
the mean inclusion forming units (IFUs) per milliliter recovered at each time point. Error
bars denote standard deviation (SD) on a log10 scale.
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Figure 2-2. C57BL/6 pathology severity scores 49 days post-primary C.
muridarum intravaginal infection.
Note: Solid bars represent the mean severity score for each treatment group. Symbols
represent individual animals. Differences between treatment groups were observed by
one-way analysis of variance (ANOVA) with post-hoc analysis using a Tukey-Kramer
Multiple Comparison test. * denotes p < 0.05 at 95% confidence interval of difference. **
denotes p < 0.01 at 95% confidence interval of difference. No difference was observed
between untreated animals and animals treated at 14-28d, 28-42d, and 35-49d. These data
are representative of multiple experiments.

25

primary infection displayed reduced disease scores (mean of 1, mild disease) when
compared to moderately diseased untreated animals and late treatment groups. In
addition, the severity of upper genital tract complications followed the same trend
established with the development of chlamydiae-specific immune responses (Figure 2-3).
In treatment groups where Chlamydia- specific antibody titers were observed as
determined by FLISA analysis, chlamydiae-related genital pathology was more severe.
Total anti-chlamydial IgG antibody titer was undetectable in early treated animals and
was significantly different in comparison to untreated animals and animals treated at 1428d, 28-42d, and 35-49d. Anti-chlamydial IgG levels resembling those of untreated
controls suggested a role for immune-mediated upper tract pathology in the development
of adverse disease outcomes.
Given the importance of anti-chlamydial Th1-dominant adaptive responses in the
resolution of chlamydiae genital infection [181] [182] [183] [184], we evaluated the
effects of antibiotic intervention on isotype switching as a marker for Th1 verses Th2
biased responses in a FLISA assay with C. muridarum-infected HeLa 229 cells as
antigen. IgG isotypes were undetectable following early treatment but data for untreated
and late treated animals strongly suggested a Th1 bias, evidenced by IgG2 dominance,
regardless of the onset of antibiotic intervention (Figure 2-4). Collectively, these data
implicate a bias for Th1 immunity irrespective of severe disease development or the
initiation of anti-chlamydial drug intervention.
Disease Severity Following Reinfection in Antibiotic-Treated Mice
Repeated infections are common in women and early treatment and have been
postulated to increase reinfection susceptibility on the population level [163] [185] [186].
Therefore, it was important to assess whether immune arrest during primary infection
contributed to disease severity post-secondary infection in our model. As a result, mice
were rechallenged 56 days after primary vaginal encounter to assess disease severity
following repeated infection. The animal groups are reflective of the onset of antibiotic
treatment during primary infection as animals did not receive treatment during the
secondary infection course. Gross examination of early treatment samples showed
significant differences in the magnitude and localization of Chlamydia-induced
pathology. Data presented in (Figure 2-5) show that reinfected animals treated at day
zero during primary infection had a mean disease severity score of 1.6, indicating mild to
no disease. Conversely, animals treated at days fourteen, twenty-eight, and thirty-five
displayed moderate to severe disease, with mean severity scores ranging from 2-3.1. To
ascertain differences in the localization of disease, we separately scored uterine horn
(Figure 2-6A) and oviduct (Figure 2-6B) pathology. Early treatment resulted in
significantly less endometrial disease when compared to untreated controls or animals
treated at fourteen, twenty-eight, and thirty-five days post primary infection. Gross
evaluation of the oviduct pathology revealed mild disease irrespective of the onset of
treatment.
In contrast to human isolates, C. muridarum may result in pathology and
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Figure 2-3. Total Immunoglobulin G (IgG) antibody response 49 days postprimary C. muridarum intravaginal infection.
Note: Bars represent mean fluorescent light units (FLUs) for each treatment group.
Differences between treatment groups were observed by one-way analysis of variance
(ANOVA) with post-hoc analysis using a Tukey-Kramer Multiple Comparison test. **
denotes p = 0.001 at 95% confidence interval of difference.
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Figure 2-4. Immunoglobulin G (IgG) isotype responses 49 days post C.
muridarum intravaginal infection in mice intraperitoneally treated with doxycycline.
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Figure 2-5. Incidence and severity of upper genital tract sequelae in antibiotictreated mice 28 days post-secondary infection.
Note: Solid bars represent the mean severity score for each treatment group. Symbols
represent individual animals. Data depicted here represents trends seen in multiple
experiments.

29

Figure 2-6. Incidence and severity of uterine horn and oviduct sequelae in
antibiotic-treated mice 28 days post-secondary infection.
Note: Solid bars represent the mean severity score for each treatment group. Symbols
represent individual animals. Data depicted here represents trends seen in multiple
experiments.
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infertility after a single infection in mice [187]. Consequently, we questioned whether the
the increase in disease severity following secondary infection was a result of primary
disease worsening over time or if repeated infection compounded sequelae severity. To
determine whether secondary challenge resulted in more severe disease when compared
to disease post primary infection, we compared weight ratios as a measure of objective
disease severity for three independent untreated groups as weight positively correlated
with disease severity score (Figure 2-7). As depicted in (Figure 2-8), untreated C.
muridarum challenged animals were sacrificed fifty-six days post primary infection
(Prim56) and were compared to untreated C.muridarum challenged mice sacrificed one
hundred and twelve days post primary infection (Prim112). Prim56 and Prim112 mg/g
ratio means remained stable despite a fifty-six day gap between sacrifice dates. Albeit not
statistically significant, untreated C. muridarum challenged animals sacrificed fifty-six
days post-secondary infection (Sec56), displayed an increase in mg/g ratio when
compared to animals that only received primary infection. These data suggest severe
disease is compounded with repeated chlamydial exposure as opposed to residual primary
disease progressively worsening over time.
IL-4 Is Detectable Late Following Reinfection and Positively Correlates with Disease
Severity in Antibiotic-Treated Mice
Little is known about the cytokine milieu in the late stages of recurrent
chlamydial infection. To address the question of which, if any, cytokines were detectable
systemically during reinfection cycles, IFN-gamma, TNF-alpha, GM-CSF, IL-1B, IL-2,
IL-4, IL-6, IL-8, IL-10, and IL-12 were simultaneously analyzed from individual sera
samples collected from mice sacrificed 56 days post-secondary infection. Our results
implicate a relatively short-lived TH1 response as suggested by a dominant IgG2 antibody
response (Figure 2-2) and unremarkable detection of IFN-gamma, TNF-alpha, GM-CSF,
IL-1B, IL-2, and IL-12 post recurrent infection (See appendices). Interestingly, IL-4, a
potent inducer of TH2 immunity and a key defensive player against extracellular
pathogens, was detected in the circulation and positively correlated with an objective
measure of disease severity, weight ratios (Figure 2-9). Moreover, IL-4 detection in the
observed sera analytes gradually increased with the deferred treatment of primary
infection suggesting a TH2-independent role for IL-4 in this model.
Chlamydia and Cellular Infiltrates Following Reinfection in Antibiotic-Treated Mice
Genital tract sections were stained with H&E, NIMP-R14, CD68, CD4, or
Toluidine to identify abundant cell types present in the genital tract after recurrent
infection, including potential populations of known IL-4 secreting cells. Late treated
tissues stained with neutrophil-specific marker, NIMP-R14, revealed dense
polymorphonuclear populations when compared to the residential populations observed
in uninfected, untreated controls. Tissues excised from early treated animals
(Figure 2-10B) displayed far fewer neutrophils than late treated groups (Figure 2-10A).
Levels of T-cells expressing CD4 and macrophages expressing CD68 were comparable to
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Note: Pearson’s correlation was used to determine whether a relationship existed between
severity scoring and weight ratio variables. Solid line represents the line of best fit. Blue
circles represent individual mice (N=30). Red box highlights a significant positive
correlation between the two variables, weight ratios and total disease severity, using a
two-tailed analysis at 95% confidence interval of difference.
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Figure 2-8. Comparative analysis of weight ratios post-primary and secondary
sacrifice in untreated intravaginally infected C57BL/6 mice.
Note: Disease severity was assessed by dividing individual genital tract weights (in
milligrams) by the corresponding total weight of the animal (grams) as described in
Materials and Methods. Bars represent the mean weight ratio from three independent
studies for each infection cycle/time group while error bars correspond to the standard
error of the mean (SEM). Prim56 animals (N=3) were sacrificed 56 days post primary
infection. Prim 112 animals (N=8) were sacrificed 112 days post-primary infection.
Sec30 animals (N=9) were sacrificed 56 days post-secondary infection, totaling 112 days
post initial chlamydial exposure.
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Figure 2-9.

Systemic IL-4 post recurrent infection.

Note: Sera collected by submandibular bleed post-secondary infection was subjected to
Luminex 10-Plex analysis to determine the cytokine milieu during late stages of recurrent
infection. Individual samples were plated in duplicate and bars represent the mean IL-4
concentration for each group (Panel A). To determine whether IL-4 correlated with
disease, Pearson’s correlation was used (Panel B). A significant positive correlation (p=
0.0462) was observed when IL-4 was plotted against the weight ratios of corresponding
animals (N=30). Solid black line represents the line of best fit.
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Figure 2-10. Neutrophil infiltrates post-secondary infection.
Note: Immunohistochemistry evaluation using NIMP-R14, a neutrophil-specific marker,
of genital tract samples taken 56 days post-secondary C. muridarum infection revealed
marked increases in neutrophil influx in untreated controls (Panel A, x20) when
compared to early treatment groups (Panel B, x20) and normal, non-infected tissue (Panel
C, x20). Representative samples from each group are shown.
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levels observed in untreated, uninfected controls (data not shown) assessed at the same
time-point.
As previously mentioned, we detected unexpected concentrations of systemic IL4 (Figure 2-9) despite seeing the antibody surrogate marker for TH1-related cytokines,
IgG2 (Figure 2-4). As a result we sought to histologically identify known IL-4 producing
cell populations. Using Toluidine Blue stain we identified a treatment dependent increase
in genital tract mast cell populations, the number of mast cells increased the longer
treatment was deferred (Figure 2-11). Furthermore, there was a significant correlation
(p= 0.0090) between the severity of disease as assessed by weight ratios and mast cell
density (Figure 2-12). We also identified eosinophil infiltrates in H&E stained genital
tissue preparations but no statistically significant association was observed (Figure 2-13).
Discussion
In this study, the main objective was to integrate various Chlamydia observations
into a single, comprehensive mouse model of chlamydial genital infection. The
reproductive health of women is of particular concern with current CDC Chlamydia
surveillance data indicating increases in reported chlamydial infections, perhaps, in part,
as a result of rapid antibiotic intervention. In contrast, rising infection rates are coupled
with reduced complication rates in screened populations [131] [134] [188] despite
evidence of adverse complications being linked to multiple or prolonged chlamydial
exposures in human epidemiological studies [176] [177] [179]. Collectively, these
observations underscore the importance of determining the impact of antibiotic
intervention on the development of severe upper tract disease following repeated
infection.
In this C. muridarum model of genital infection, we showed that mice
intravaginally infected and treated early during primary infection displayed rapid
bacterial clearance kinetics in the lower genital tract, significantly reduced antichlamydial IgG titer, and virtually no upper genital tract disease. These results verify and
validate a previous antibiotic study in C57BL/10 mice that concluded early antibiotic
treatment reduced the development of natural immunity [162]. Our study expands on this
model by extending observation on disease severity to post-secondary infection and by
defining differences in disease localization. Mice treated early during primary infection
displayed mild disease severity scores (mean score of 1) in both uterine horn dilation and
hydrosalpinx formation. Conversely, untreated infected mice and mice treated later
during primary infection displayed moderate to severe disease severity scores in the
uterine horn (mean range of 2 to 3.3). However, in the oviduct, significant differences
were not observed between treatment groups suggesting either chlamydiae-related
responses differ between these two tissues or severe endometrial disease limits the
likelihood of oviduct disease. Interestingly, and perhaps not logically, mice that received
treatment midway through the natural course of an active primary infection (14-28d)
displayed elevated disease severity scores in both the uterine horn and the oviduct, albeit
not significantly different from other treatment groups. So far, we have not studied this
phenomenon extensively but eradication of the organism soon after the initiation of
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Figure 2-11. Mast cell infiltrate post-secondary infection.
Note: Immunohistochemistry evaluation using Toluidine Blue, a mast cell identifying
stain, of genital tract samples taken 56 days post-secondary C. muridarum infection
revealed mast cells in all of the groups assessed. Organ specific mast cell density was
determined by manually counting positively stained granulated mast cells in the genital
tissue. Bars represent mean mast cell counts for each treatment group.
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Figure 2-12. Mast cell infiltrate verses systemic IL-4 correlative analysis.
Note: Organ specific mast cell density was determined by manually counting positively
stained granulated mast cells in the genital tissue. A strong positive correlation between
systemic IL-4 and mast cell infiltrate (r= 0.6682, p= 0.0090) was observed using
Pearson’s correlation two-tailed testing at a 95% confidence interval.

38

Figure 2-13. Eosinophil infiltrate post-secondary infection.
Note: Immunohistochemistry H&E staining of genital tract samples taken from mice 56
days post-secondary infection with C. muridarum revealed eosinophils in untreated,
uninfected animals (A, x40), early treatment groups (B, x20), and late treatment groups
(C, x30). Thirty-six fields were randomly selected and counted (12 cervical fields, 12
uterine horn fields, and 12 oviduct fields.) for each sample. No significant correlation
between the number of eosinophils present in the genital tract and systemic IL-4 was
found (D). Representative samples from each group are shown.
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antibiotic treatment and detectable humoral antibody responses fail to explain the
observation. Future characterization of the model, including but not limited to the cellular
immune response, is of interest and should be investigated to elucidate the underlying
immune mechanism involved.
Histological analyses of various cellular populations suggest an influx of
polymorphonuclear cells during late stages of recurrent urogenital infection. Using
NIMP-R14, a neutrophil –specific marker, we observed an increase in neutrophils among
late treated animals when compared to uninfected controls and early treated groups. This
follows previous observations by our group [189] [190] and others [191] [192] [193] that
cellular infiltrates composed of neutrophils correlate with the development of more
severe disease. Data from our studies illustrate the sustained presence of neutrophils
during late stages of recurrent infection (fifty six days post-secondary infection) and
suggest that disease severity may be a function of sustained innate reactivity rather than
the TH1-biased response that was observed in all animals, irrespective of disease severity.
This expands the current paradigm of neutrophil influx as an early marker of infection
into a potential mediator of disease outcomes and implies that modulation of neutrophil
influx may improve chlamydiae-related disease severity and may be investigated as a
potential way to improve reproductive health.
Perhaps the most interesting finding in this investigation was the systemic
detection of TH2-linked immune regulator, IL-4 (Figure 2-9), with greater detection of
IL-4 corresponding with late treatment groups displaying the most severe disease. While
our data support the current dogma of TH1-type responses playing a role in the resolution
of infection as evidenced by a detectable IgG2-biased chlamydial-specific antibody
response (Figure 2-4), they also suggest an alternative TH2 independent role for IL-4
production during recurrent chlamydiae infection. Our data illustrate the development of
chlamydial-induced genital tract pathology, with the severity of disease increasing the
longer you defer antichlamydial treatment and with multiple rounds of chlamydial
exposure. Following secondary exposure, a scenario in which we report exacerbated
genital tissue damage, large amounts of IL-4 were detectable and gradually increased as
the magnitude of disease increased. Our data compliments observations made by Holland
et al of increased TH2-related cytokine production in patients with more severe disease
[194]. Miquel et al reported that women with a history of Chlamydia trachomatis
infection secrete cytokines consistent with TH2 immunity, specifically significant levels
of IL-4, in response to ex vivo stimulation [195]. Collectively, these observations lead us
to hypothesis a role for IL-4 in tissue repair. Recent reports have linked IL-4 to tissue
repair and wound healing by alternatively activating macrophages and stimulating the
expansion of IL-4 producing cells [196] [197] [198] [199] [200]. In line with these
reports, we were able to detect both eosinophils and mast cells, known IL-4 producing
cells, in our model. Furthermore, it is important to keep in mind that we detected a TH1
response, at least early on during infection, as evidenced by an IgG2 biased antibody
response. This suggests that the production of IL-4 occurs later in the immunological
cascade (following the production and secretion of chlamydial-specific antibody), which
decreases the likelihood of IL-4 initiating the genital tract tissue damage observed (the
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idea of IL-4 being an injury promoter) and points to the possibility of IL-4 playing a role
in “injury response.”
While we present data in support of the IL-4-driven injury response hypothesis,
further study is necessary for hypothesis validation and mechanism delineation. For
instance, we proposed the transient production of TH1-related cytokines led to the
detection of IgG2 isotypes during early infection cycles. Time course studies following
the onset and dissipation of TH1-linked cytokines and IL-4 are key to verifying that
proposal. While we know eosinophils and mast cells are capable of producing IL-4 and
their presence in the genital tract implicates them as IL-4 sources, it would be useful to
know if they are actually responsible for producing the detected IL-4. This can be
accomplished by microarray analysis of IL-4 gene expression and subsequent ELISA
assay for IL-4 production ex vivo. Additional experiments may also include looking at
the upregulation of genes known to particulate in repair signaling pathways in genital
tract-derived tissue and dispelling the possibility of IL-4 participating in the initial stages
of disease development using IL-4-/- knockout mice.
Rapid antibiotic treatment is a key component of current Chlamydia control
initiatives that may influence infection rates and, more importantly, disease outcome
trends on the population level, but assessing the impact of antibiotic intervention on
severe disease development is difficult to address due to ethical concerns associated with
delaying or withholding treatment in the human population. To this end, we interrogated
the murine model for its potential to serve as a translational bridge between populationbased epidemiology and previous animal and human studies. Our results reaffirm the
benefit of rapid antibiotic intervention in Chlamydia control efforts and suggest an added
benefit during repeated infection even in the absence of antibiotic treatment. Although
early-treated mice developed some upper tract disease after re-challenge, it was
substantially less severe than the disease observed in groups where treatment was
delayed. This is of particular interest since previously screened and treated women
commonly re-enter susceptible sexual networks, acquire a secondary infection, and fail to
seek treatment due to the asymptomatic nature of Chlamydia trachomatis infection. Most
importantly, we provide support for IL-4 dependent tissue damage response following the
induction of chlamydial-induced genital tract complications. We conclude that the
integrated murine model is useful for studying the efficacy of antibiotic intervention at
varying time-points with respect to disease severity but requires further characterization
to elucidate potential mechanisms by which chlamydial pathogenesis occurs and is
regulated, particularly as it pertains to the induction of IL-4. The dichotomy between cellmediated chlamydiae-related immune responses may not be as straightforward as we
previously thought.
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CHAPTER 3.

CHLAMYDIAL GENITAL TRACT SEQUELAE IS AGE AND
STRAIN-DEPENDENT
Introduction

Sexually transmitted Chlamydia trachomatis is the causative agent of the most
commonly reportable disease in the United States [147] and a small percentage of
infected women develop reproductive and gynecologic complications such as chronic
pelvic pain [170, 201-204], pelvic inflammatory disease (PID)[170] [201] [205] [206],
involuntary infertility [170] [172] [201] [203] [206], and ectopic pregnancy [170] [172]
[176] [201] [204] [206]. While many factors contribute to individual disease variability to
chlamydiae [74] [75] [100] [207], the effects of biological determinants such as genetic
predisposition and host age at the time of infection [208] [209] are largely unknown.
Identification of host genetic factors is central to improving the quality of current disease
animal models and understanding chlamydial-induced disease heterogeneity. Moreover,
murine genetic studies may implicate novel pathway targets for individualized
therapeutic intervention in humans.
Inbred mouse models have been extensively used to study host contributions to
chlamydiae infection susceptibility [74] [75] [210] [211] [212] [213] [214] [215].
Cytokine induction and expression, H2 haplotypes, chlamydial species, and Th-1mediated responses have all been identified as factors that contribute to varying murine
susceptibility. More recently, unbiased genome-wide approaches have been used to
identify p47 GTPase genes encoded on chromosome 11 that confer resistance in mice to
systemic models of C. trachomatis and C. psittaci infection, respectively [190] [216]
[217]. Since, Miyairi et al have combined the high throughput forward genetic approach
of BxD recombinant inbred strains with Bayesian network modeling to identify host
pathways that modulate susceptibility to systemic chlamydial infection [78].
In the present investigation, we considered the age of the animal at time of
infection and the genetic composition of the host when identifying differences in upper
genital tract disease severity. We conclude that age and host genetic make-up are both
important determinants of disease.
Materials and Methods
Mice
Seven week old C57BL/6J (H-2b) and DBA/2J (H-2d) female mice (referred to as
≤9wk animals) were commissioned from The Jackson Laboratory (Bar Harbor, ME,
USA). Fourteen to 32-week old C57BL/6J and DBA/2J female mice (referred to as
>14wks) were bred and maintained at our facility, which is fully accredited by the
Association for Accreditation and Assessment of Laboratory Animal Care International.
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The Animal Care and Use Committee at The University of Tennessee Health Science
Center (Memphis, TN) approved all animal studies.
Chlamydia Strain
The Chlamydia muridarum (Weiss) strain was propagated in HeLa 229 cells and
elementary bodies (EBs) were purified from infected cells by 30% density gradient
centrifugation in Renograffin (E.R. Squibb and Sons, Princeton, NJ). Chlamydial titer
was evaluated by infecting HeLa 229 cells and enumerating by indirect fluorescence
microscopy as previously described. Stocks were stored at -80oC until use.
Chlamydia muridarum Infection
DBA/2J, C57BL/6J, and BXD mice were pretreated with progesterone to
synchronize the estrous cycle and stabilize the target genital epithelium. Pretreatment
consisted of two subcutaneous injections of 2.5 mg medroxyprogesterone acetate
injectable suspension (Sicor, Irvine, CA) in 0.1 mL phosphate buffered saline (PBS),
given at 10 and 3 days prior to infection. Mice were inoculated with 5000 inclusionforming units (IFUs) contained in 5 uL sucrose phosphate-buffered glutamic acid (SPG)
via the vaginal vault with a filtered micropipettor on day 0. Five animals from each group
(DBA/2J-≤9wks, DBA/2J->14wks, C57BL/6J-≤9wks, and C57BL/6-2J->14wks) were
sacrificed 40-days post infection. For rechallenge studies, five animals from each group
were progesterone treated at day 30 and intravaginally challenged with 5000 IFU at day
40. All rechallenged animals were euthanized 30 days post reinfection, seventy days postprimary infection.
Pathology Assessment
Individual mice were weighed to obtain total body weight in grams. In situ
macroscopic examinations were performed for evidence of upper genital tract
abnormalities immediately following sacrifice. Genital tissues were then aseptically
removed, photographed, and weighed to obtain organ weight in micrograms. Severity
scores were determined for the uterine horn and oviducts separately: 0, no significant
dilatation; 1, mild dilatation of a single cross-section; 2, one to three dilated crosssections; 3, greater than three dilated cross-sections; 4, confluent pronounced dilation.
Scores assigned to individual mice were averaged to obtain the mean severity score for
each group of animals. Weight ratios (organ weight-milligrams/ total body weight-grams)
were used as an objective validation tool for upper genital tract severity scoring.
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Results
C57BL/6J Exhibit Age-Dependent Upper Genital Tract Sequelae Post-Primary
Intravaginal Infection
DBA/2 and C57BL/6 female animals of varying ages were intravaginally infected
with C. muridarum as described in materials and methods. Individual mice were scored
according to the localization of disease 40 days post infection. Nine out of 20 animals
(45%) assessed developed hydrosalpinx with B6-≤ 9wk animals displaying significantly
more oviduct disease (p< 0.001) when compared to all other animal groups (Figure
3-1A). Twenty percent of DBA/2, regardless of age, displayed mild oviduct dilatation
indicated by a mean severity score of 0.23. Conversely, discordant oviduct severity
scores were observed among C57BL/6J-≤ 9wk and C57BL/6J->14wk groups. A
moderate oviduct severity score of 2.2 was observed in B6-≤ 9wk animals while B6>14wk animals displayed mild oviduct involvement with a mean score of 0.4. No
significant differences were observed in endometrial dilatation among groups,
irrespective of inbred strain or age (Figure 3-1B).
Secondary Intravaginal Infection Exacerbates Chlamydial-Induced Upper Genital
Tract Complications
We hypothesized that recurrent chlamydial exposures would result in worse
disease when compared to animals that received primary infection alone. To test this
hypothesis, DBA and B6 female mice were intravaginally infected at day 0 and
rechallenged at day 40 as described in materials and methods. Thirty days after
rechallenge, genital tissues were aseptically harvested and assessed for oviduct and
uterine horn dilatation. As we hypothesized, secondary disease exacerbated negative
disease outcomes in both strains and age groups (Figure 3-2) when compared to the
corresponding groups that only received a primary infection (Figure 3-1). Sixteen out of
21 animals (76%) examined after secondary infection developed oviduct pathology as
opposed to 45% of primarily infected animals. Fourteen out of 21 animals (66.6%)
examined after secondary infection developed uterine horn pathology as opposed to 30%
of primarily infected animals.
C57BL/6 Mice Are More Susceptible to Chlamydial-Induced Upper Genital Tract
Complications When Compared to DBA/2J Mice
DBA and B6 female mice were intravaginally infected at day 0 and rechallenged
at day 40 as described in materials and methods. Thirty days after rechallenge, genital
tissues were aseptically harvested and assessed for oviduct and uterine horn dilatation.
Oviduct disease observed in C57BL/6-≤ 9wk animals was significantly worse (mean
severity score 3.6) than that observed in DBA/2-≤ 9wk and DBA/2->14wk animals with
mean scores of 0.8 and 1.2, respectively. Additively, C57BL/6->14wk animals displayed
significantly more severe oviduct disease than that seen in DBA/2-≤ 9wk or DBA/2
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Figure 3-1.
infection.

Upper genital tract disease incidence and severity post-primary

Note: DBA/2 and C57BL/6J female mice were intravaginally infected with Chlamydia
muridarum as described in materials and methods. Forty days after infection, mice were
sacrificed and pathology was assessed grossly. The left figure (Panel A) displays oviduct
disease severity and disease incidence by inbred strain and age group. The right figure
(Panel B) displays uterine horn disease severity and disease incidence by inbred strain
and age group. 5 animals were assessed per group and bars indicate mean severity scores.
* and ** indicate significant differences (p≤ 0.01 and p≤ 0.001) as determined by oneway ANOVA with post hoc Newman-Keuls Multiple Comparison Test. Data are
representative of two independent studies.
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Figure 3-2.
infection.

Upper genital tract disease incidence and severity post-secondary

Note: DBA/2 and C57BL6 female mice were intravaginally infected and rechallenged
with Chlamydia muridarum as described in materials and methods. Thirty days postsecondary infection, mice were sacrificed and pathology was assessed grossly. The left
figure (Panel A) displays oviduct disease severity and incidence by inbred strain and age
group. The right figure (Panel B) displays uterine horn disease severity and incidence by
inbred strain and age group. 5-6 animals were assessed per group and bars indicate mean
severity scores. * indicate significant differences (p<0.01) as determined by one-way
ANOVA with post hoc Newman-Keuls Multiple Comparison Test. Data are
representative of two independent studies.
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->14wk animals. Although uterine horn severity assessments did not result in statistically
significant differences, B6-≤ 9wk animals consistently displayed moderate disease
severity as indicated by a mean score of 2 while B6->14wk endometrial involvement was
comparable to that observed in DBA/2 animals.
To remove any unintentional disease bias imposed by using the quantitative
severity scoring system, we assessed disease severity as a function of organ weight in
milligrams divided by total body weight in grams (Figure 3-3). We have previously
observed a direct correlation between severe disease and increased weight ratios given
genital abnormalities that involve dilatation of murine oviduct and uterine horn tissues
increase the ratio numerator value-organ weight in milligrams (Figure 2-7). Weight
ratios compliment severity score data in that secondary infection results in worse disease
when compared to animals of the same strain and age group. Moreover, C57BL/6-≤ 9wk
animals are most susceptible to chlamydial-induced upper genital tract complications
evidenced by significant differences observed in recurrent infection oviduct severity
scores and objective weight ratio analysis.
Discussion
Individual differences in disease susceptibility as a result of infectious agents
exist in the population. For example only a small subset of women with uncomplicated
chlamydial genital infection go on to develop severe upper genital tract
complications[170]. Furthermore, adolescent females are more likely to contract
Chlamydia than any reported age group [185] [218] [219]. In the United States alone, the
reported 2011 rates of sexually transmitted chlamydial infection for women between the
ages of 15-19 and 20-24 were 3416.5 and 3722.5 per 100,000 population, respectively
[147]. The reported rate for adolescents between the ages of 15-19 yrs is over five times
the national rate of 648.9 per 100,000 population and almost six times the national rate
for young women between the ages of 20-24 yrs. These rates are particularly alarming
considering the rate for women in their mid-forties to early fifties is only 35.8 per
100,000 population [147]. Taken together, current epidemiological trends highlight the
need for chlamydial models to account for biological factors such as host age when
assessing incidence and severity of chlamydiae-induced reproductive complications.
In this study, chlamydial-induced disease outcomes were largely dependent on the
mouse age and strain used to model urogenital infection. C57BL/6-≤ 9wk mice were
more susceptible to oviduct pathology when compared to DBA/2 mice as evidenced by
mean severity score post primary (Figure 3-1A) and secondary infection cycles (Figure
3-2A). In addition to extra-strain disease variation, intra-strain disease variation among
B6 was shown to be age-dependent in the oviduct post primary infection and, albeit not
statistically significant, in the oviduct and uterine horn post-secondary infection. In
addition to the four-tiered semi-quantitative severity scoring system, these results were
objectively validated with weight ratio analysis (Figure 3-3). BL/6-≤ 9wk animals
display significantly more disease as evidenced by weight ratios when compared to
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Figure 3-3. Weight ratio disease severity validation post-primary and secondary
intravaginal infection.
Note: DBA/2 and C57BL6 female mice were intravaginally infected and rechallenged
with Chlamydia muridarum as described in materials and methods. Weight ratios were
determined by dividing individual organ weights (milligrams) by total body weight
(grams). Ratios were averaged to calculate the mean value for each group (indicated by
bar). Error bars depict the standard error of the mean. * indicate significant differences
(p< 0.05) as determined by one-way ANOVA with post hoc Newman-Keuls Multiple
Comparison Test. ** indicate significant differences (p< 0.01) as determined by one-way
ANOVA with post hoc Newman-Keuls Multiple Comparison Test. Data are
representative of two independent studies.
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> 14wk animals with the same genetic background. Interestingly, disease severity as a
function of weight observed in DBA/2 animals remained consistent irrespective of age or
disease localization.
While inter-strain susceptibility variations have been appreciated for some time
[74] [75] [210] [220], our studies suggest C57BL/6 animals are susceptible to
chlamydial-induced genital tract complications when compared to DBA/2 mice as
determined by semi-quantitative severity scoring (Figures 3-1 and 3-2) and weight ratios
(Figures 3-3). Kaltenboeck et al also found that C57BL/6 animals were susceptible to
chlamydial-induced disease using a respiratory murine model of infection [221]. In their
studies C57BL/6 mice developed severe pneumonia while BALB/C mice were
completely void of symptoms following intranasal priming with C. psittaci and
subsequent challenge. Interestingly, our results and those seen in the Kaltenboeck model
conflict with genital studies proposing a resistant phenotype for C57BL/6 when
compared to C3H and BALB inbred strains, both of which are commonly referred to as
susceptible strains given their increased chlamydial shedding and longer courses of
infection when compared to C57BL/6 mice. Although we have not delineated a
mechanism for the results seen in our study, immunological validation is warranted and
currently underway. The discrepancies observed between our results and those published
by others may also be attributed, at least in part, to differences in the strains of Chlamydia
used, inoculum dosage, murine strains, multiple rounds of infection, and variation in what
is defined as resistance or susceptibility (I. E. reduced shedding, shorter infection course,
infertility, eradication of the infectious agent in the lower and upper genital tract, or the
development of upper genital tract sequelae).
As many researchers developing infectious disease models, we are interested in
identifying human correlates of phenotypic differences seen in our model. Studies are
currently underway using B (C57BL/6) x D (DBA/2J) recombinant inbred mouse strains
to identify genetic factors that may modulate disease susceptibility in an age-dependent
manner. By interrogating the GeneNetwork database using a forward genomic approach,
we hope to identify genes associated with the modulation of oviduct and uterine horn
disease severity in an age and strain dependent manner. More importantly, we are
interested in identifying human correlates for the potential murine-derived phenotypicgenetic links observed in our model.
While studies aimed at delineating causal mechanisms for the age and strain
dependence reported here are currently underway, these initial observations have
immediate implications for the use of mouse models in understanding chlamydialinduced disease. Furthermore, these data suggest that the host genetic contribution to
genital pathogenesis may be more complex than previously appreciated.

49

CHAPTER 4. IMMUNIZATION WITH C. MURIDARUM OUTER MEMBRANE
COMPLEX FAILS TO PROTECT AGAINST UPPER GENITAL TRACT
COMPLICATIONS IN A MURINE MODEL OF GENITAL INFECTION
Introduction
Chlamydia trachomatis is the causative agent of the most commonly reported
sexually transmitted disease in the United States, Chlamydia, and a public health threat
worldwide [56] [63] [147] [222]. Despite the overwhelming global presence of
chlamydial infection, many cases are undiagnosed due to asymptomatic infection and
may serve as a reservoir for infection [175] [223]. Regardless of whether Chlamydia
trachomatis infection is symptomatic or asymptomatic, women with genital infections
may develop long-term sequelae like pelvic inflammatory disease (PID), ectopic
pregnancy, involuntary infertility, and miscarriage [169] [170]. Antibiotic therapy is
currently effective in clearing the organism from the lower genital tract but the
emergence of antibiotic resistance, although rare, is a viable concern [224] [225] [226]
227]. Currently, rapid antibiotic intervention is a key component of Chlamydia control
programs [173] [175] and may serve as the selective pressure necessary for the evolution
of antibiotic resistant human strains. Taken together, the high rate of asymptomatic
infection and the potential for developing antibiotic resistance despite the current
availability of effective antimicrobial therapies underscore the need for a safe and
efficacious vaccine.
Trachoma vaccine trials using whole organisms, both inactivated and live, were
performed decades ago and are perhaps the most notable vaccination studies to date.
Unfortunately, a subset of individuals who were vaccinated and reexposed to Chlamydia
experienced significantly more severe disease when compared to non-vaccinated cohorts
[124] [228] [229]. While no human trials have been untaken since the trachoma study,
researchers have continued the quest to identify safe chlamydial antigens that elicit
immunological memory- the basis of all vaccines.
A number of Chlamydia trachomatis- associated antigenic proteins have been
described, particularly proteins associated with the cell surface. Many studies have
focused on developing a subunit-based vaccine using Chlamydia trachomatis major outer
membrane protein (MOMP) as the antigen [230] [231]. MOMP has been an attractive
candidate because it constitutes an approximated 60% of the total outer membrane mass
and is immune-assessable due to its location on the chlamydial surface [21] [125].
Although MOMP seemed promising, its ability to induce protection has been sketchy at
best, displaying varying protection in small animal models and higher order primates
[232] [233] [234] [235] [236] [237] [238] [239] [240] [241]. There may be several
reasons for the variation seen in the previously mentioned studies including but not
limited to the animal model and strain(s) used, immunization site, challenge route,
definition of protection (I.E. reduction in shedding, fertility, cytokine production,
antibody titer, or sequelae formation) , and antigen preparation. Indeed, one of the main
lessons taken from previous MOMP studies is that conformational integrity of the
chlamydial membrane may increase protection following chlamydiae challenge. As a
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result, we elected to use detergent-extracted chlamydial outer membrane complexes
(COMCs) as described by Caldwell et al [125] in the preliminary studies outlined later in
this Chapter. Sarkosyl-Insoluble COMC was found to be structurally intact and
maintained the shape observed in protein-rich infectious chlamydial particles, elementary
bodies (EBs).
In the pages to follow, I outline experiments evaluating the efficacy of COMC as
a potential antigen in both systemic and genital models of chlamydiae infection. As a
disclaimer, these studies are in their infancy at best and should not be interpreted as
complete studies. Several gaps exist in the experiments outlined hereafter but these data
do provide interesting tangents that may serve as the basis for future experimental
direction. To that end, our initial results in the systemic model showed promise by
negating the effects of lethal interperitoneal chlamydial doses. Conclusions originating
from studies in the urogenital murine model were more muddled when compared to the
lethal model. Despite the inconclusive nature of the genital tract model results, we
examined the potential benefits of alum, an adjuvant known to generate a TH2 cellmediated response, in the prevention of severe genital sequelae.
Materials and Methods (Systemic Lethal Model)
Mice
Female DBA/2J mice were purchased from Jackson Laboratories at 7-8 weeks of
age. They were housed in the University of Tennessee Health Science Center animal
facility and animal protocols were performed in compliance with institutional IACUC
and federal mandates.
Chlamydiae
Chlamydia psittaci 6BC was propagated in the murine fibroblast cell line L929
(ATCC; Manassas, VA) and stored at -80o C. Titers were determined by infecting L929
cells plated at a density of 2 x 105 cells/well in 24- well plates (Corning Costar
Corporation, Cambridge, MA), with tenfold dilutions of thawed stock. Infected
monolayers were incubated for 48 hours, methanol fixed, and chlamydial inclusions were
enumerated using fluorescent staining with FITC-conjugated anti-chlamydial
lipopolysaccride antibody (Fitzgerald Industries Internation Incorporated, Concord, MA).
COMC Extraction
Chlamydia psittaci 6BC COMC was purified as described by Caldwell et al [125].
In brief, C. psittaci 6BC stock was thawed at room temperature and suspended in 5mL of
pH 8 phosphate buffered saline (PBS) containing 2% dipolar ionic Zwittergonic detergent
and 1.5 mm EDTA. A dry ice bath was used to precipitate proteins and the resulting
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suspension was sonicated, in series, 3 times with 1 minute iced incubation periods
between each round of sonication. The cell suspension was incubated for 3 hours at 37o
C and ultracentrifuged at 32, 700 rotations per minute (RPM) for 1hour.
Immunization and Infection
DBA/2J mice were intramuscularly mock immunized with 100mL of sterile
Dulbecco’s phosphate buffered saline (PBS), viable whole elementary bodies (EBs) of
6BC (5 x 102 IFU in 100mL of sterile PBS), or 6BC-derived COMC (40mg total) in
100mL of PBS, respectively. Mice received a total of two immunizations at days -14 and
-7. On day 0, mice were intraperitoneally challenged with a low dose (1 x 103 IFU,
equivalent to 1000 LD50) or a high dose (1 x 105 IFU, equivalent to 100000 LD50) and
monitored for survival. Surviving animals were sacrificed 15 days post infection
irrespective of immunization regimen.
Results (Systemic Lethal Model)
Our laboratory was instrumental in developing a systemic interperitoneal model
of chlamydial disease using C. psittaci 6BC, a zoonotic to which mice are highly
susceptible. Using the systemic model Byrne and colleagues were able to elucidate basic
concepts concerning interferon-gamma and Chlamydia psittaci clearance [242] [243]
[244]. Unpublished data from our laboratory showed that doses as low as 1 EB can cause
mice to succumb to infection within 10 days of initial C. psittaci challenge. These data
provided the basis for using the systemic model of chlamydiae infection to elucidate
COMC immunogenicity. One hundred percent of mice immunized with viable 6BC
Chlamydia psittaci elementary bodies (EBs) survived challenge and recovered from
infection irrespective of the challenge dose. Conversely, all mock PBS immunized mice
succumbed to infection within 11 days of interperitoneal challenge. 20% of COMC
antigen immunized mice survived an inordinately high dose challenge and went on to
recover from infection (Figure 4-1). Moreover, 60% of mice immunized with 6BC
Chlamydia psittaci -derived antigen survived and recovered from lethal challenge
(Figure 4-2).
Despite the rigor associated with the systemic chlamydial intraperitoneal murine
model, COMC preparations were capable of eliciting partial protection against lethal
challenge. Both immunizing doses, 102 and 105 IFU, supersede the LD50 and highlight the
sensitivity of DBA/2J inbred mice to 6BC Chlamydia psittaci intraperitoneal infection as
previously illustrated by the Byrne laboratory. Collectively, these data suggested COMCinduced partial protection with homologous challenge and justified transitioning these
studies into the urogenital model which would display more subtle read-outs.
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Figure 4-1.

High dose 6BC C. psittaci systemic infection survival curve.
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Low Dose 6BC C. psittaci Interperitoneal Challenge
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Figure 4-2.

Low dose 6BC C. psittaci systemic infection survival curve.
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Materials and Methods (Urogenital Model)
Mice
Female DBA/2J mice were purchased from Jackson Laboratories at 7-8 weeks of
age. They were housed in the University of Tennessee Health Science Center animal
facility and animal protocols were performed in compliance with institutional IACUC
and federal mandates.
Chlamydiae
Chlamydia muridarum (Weiss) was propagated in the human epithelial cell line
HeLa 229 (ATCC; Manassas, VA) and stored at -80o C. Titers were determined by
infecting HeLa 229 cells seeded at a density of 2 x 105 cells/well in 24- well plates
(Corning Costar Corporation, Cambridge, MA), with tenfold dilutions of thawed stock.
Infected monolayers were incubated for 48 hours, methanol fixed, and chlamydial
inclusions were enumerated using fluorescent staining with FITC-conjugated antichlamydial lipopolysaccride antibody (Fitzgerald Industries Internation Incorporated,
Concord, MA).
COMC Extraction
Chlamydia muridarum COMC was purified as described by Caldwell et al [125].
In brief, C. muridarum stock was thawed at room temperature and suspended in 5mL of
pH 8 phosphate buffered saline (PBS) containing 2% dipolar ionic Zwittergonic detergent
and 1.5 mm EDTA. A dry ice bath was used to precipitate proteins and the resulting
suspension was sonicated, in series, 3 times with 1 minute iced incubation periods
between each round of sonication. The cell suspension was incubated for 3 hours at 37o
C and ultracentrifuged at 32, 700 rotations per minute (RPM) for 1hour.
Immunization and Infection
DBA/2J mice were intramuscularly immunized with 100mL of sterile Dulbecco’s
phosphate buffered saline (PBS), 100mL of sterile Dulbecco’s phosphate buffered saline
(PBS) and 25ug of alum, live C. muridarum elementary bodies (5 x 102 IFU in 100mL of
sterile PBS), 25ug of Chlamydia muridarum-derived COMC in 100mL of PBS, or 25ug
of Chlamydia muridarum-derived COMC in 100mL of PBS and 25ug of alum. Mice
received a total of two immunizations at days -14 and -7. One week prior to challenge,
the estrous cycle was synchronized by subcutaneous injection of 2.5mg of
medroxyprogesterone acetate (Sicor, CA). On day 0, mice were intravaginally challenged
with 2 x 103 IFU, a non-lethal dose of C. muridarum.
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Results (Urogenital Model)
C. muridarum and C. psittaci-derived COMC preparations were compared by
commassie-stained SDS-Page gel and displayed comparable banding patterns
(Figure 4-3). As expected, animals intramuscularly immunized with viable whole C.
muridarum elementary bodies and intravaginally challenged with 5 x 103 IFU displayed
the most severe disease when compared to other immunization groups as evidenced by
dilation of the uterine horns and reddening of the genital tract (Figure 4-4A). Mock
immunized animals (Figure 4-4B) also displayed fluid accumulation in the uterine horn,
although to a lesser extent when compared to the live immunized group. COMC
immunized animals displayed less severe disease when compared to live immunized
groups but still displayed mild to moderate dilation and reddening (Figure 4-4D). While
animals immunized with COMC-alum displayed mild reddening, dilation was not
observed (Figure 4-4E). Lastly but most intriguingly, animals immunized with the PBSalum combination displayed no dilation or substantial reddening (Figure 4-4C).
While we hypothesized that alum would augment protection elicited by COMC
antigen immunization despite its polarity toward a Th2-type response, we were perplexed
by the observation seen in PBS-alum immunized groups. Unexpectedly, the alum
adjuvant seemed to negate the development of severe genital tract sequelae induced by
exposure to C. muridarum intravaginal infection. The study described below followed as
an attempt to assess whether alum alone was capable of negating the development of
upper genital tract sequelae following C. muridarum intravaginal infection.
Materials and Methods (Alum Study)
Mice
Female C57BL/6J mice were purchased from Jackson Laboratories at 7-8 weeks
of age. They were housed in the University of Tennessee Health Science Center animal
facility and animal protocols were performed in compliance with institutional IACUC
and federal mandates.
Chlamydiae
Chlamydia muridarum (Weiss) was propagated in the human epithelial cell line
HeLa 229 (ATCC; Manassas, VA) and stored at -80o C. Titers were determined by
infecting HeLa 229 cells seeded at a density of 2 x 105 cells/well in 24- well plates
(Corning Costar Corporation, Cambridge, MA), with tenfold dilutions of thawed stock.
Infected monolayers were incubated for 48 hours, methanol fixed, and chlamydial
inclusions were enumerated using fluorescent staining with FITC-conjugated antichlamydial lipopolysaccride antibody (Fitzgerald Industries Internation Incorporated,
Concord, MA).
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Figure 4-3. Comassie stained SDS-Page gel of C. muridarum (MoPn)-derived
COMC and C. psittaci (6BC)-derived COMC preparations.
Note: Chlamydiae COMC preparations were extracted as previously described in Chapter
4. Protein concentrations were determined by Modified Lowry Protein Assay and
visualized by SDS-Page gel. Molecular weight protein standard (shown on left) were
used to approximate the molecular weight of visualized bands.
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Figure 4-4.

C. muridarum-derived COMC immunization study gross pathology.

Note: Representative photos of genital gross pathology post homologous C. muridarum immunization and challenge. Photo (A) is
representative of live immunizations. Photo (B) is representative of mock immunized animals. Photo (C) is representative of mockalum immunized animals. Photo (D) is representative of COMC immunized animals and photo (E) represents animal cohorts
immunized with COMC-alum. Black arrows point out selected areas of dilatation, reddening, and hydros0alpinx formation.

58

Immunization and Infection
C57BL/6J mice were intramuscularly immunized with 100mL of sterile
Dulbecco’s phosphate buffered saline, 100mL of sterile Dulbecco’s phosphate buffered
saline and 25ug of alum (Thermo Scientific), live C. muridarum elementary bodies (5 x
102 IFU in 100mL of sterile PBS), or a mixture of live C. muridarum (5 x 102 IFU in
100mL of sterile PBS) and 25ug of alum. Mice received two immunizations one week
apart and were treated subcutaneously with 2.5mg of medroxyprogesterone acetate
(Sicor, CA) at days -9 and -3 to synchronize the esterous cycle and enhance mouse
susceptibility to chlamydial infection. On day 0, mice were intravaginally challenged
with 2 x 103 IFU Chlamydia muridarum in 10uL of PBS. Animals that were immunized
and challenged were sacrificed 35 days post infection. Immunized animals that did not
receive an infection were sacrificed 21 days after day 0.
Pathology Assessment
Before removing the genital tissue, an in situ gross examination was performed
for evidence of chlamydial-induced abnormalities such as uterine horn dilation and
hydrosalpinx formation. Genital tracts were aseptically removed, photographed,
subjected to macroscopic inspection, and assigned a severity score on the day of sacrifice.
Results (Alum Study)
Immunogens without Intravaginal Chlamydia muridarum Challenge Do Not Induce
Severe Upper Genital Tract Sequelae Formation
Female C57BL/6J mice were intramuscularly immunized with alum adjuvant,
viable C. muridarum and alum adjuvant, viable C. muridarum, or mock immunized with
sterile PBS according to the timeline displayed in (Figure 4-5). Genital tracts from each
animal were aseptically removed, weighed, photographed, and grossly assessed for upper
genital tract sequelae formation three weeks after day 0. Two non-immunized C57BL/6
mice, of the same age and gender, were used as a reference. As hypothesized,
hydrosalpinx formation was not observed in any of the immunization groups (Figure
4-6). Negligible increases in dilation of the uterine horns were observed in mock, C.
muridarum and alum adjuvant, and C. muridarum alone immunized animals. Although
these increases were minimal, they were documented by granting the lowest severity
score possible (Figure 4-7). Overall, genital tract tissues, regardless of immunization
group were comparable to that observed in the two non-immunized, non-challenged
reference samples.

59

Figure 4-5.

Alum study experimental timeline.
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Figure 4-6.

Oviduct pathology severity of non-challenged immunized groups.

Note: Solid line represents the mean of each immunogen group. Symbols represent
individual mice (N=5 per group except for normal control).
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Figure 4-7.
groups.

Uterine horn pathology severity of immunized, non-challenged

Note: Solid bars represent the mean severity score for each immunogen group. Symbols
represent individual animals (N=5 per group except for normal controls).
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Alum Alone Does Not Negate the Development of Severe Upper Genital Tract
Complications
Female C57BL/6J mice were intramuscularly immunized with alum adjuvant,
viable C. muridarum and alum adjuvant, viable viable C. muridarum, or mock
immunized with sterile PBS according to the timeline displayed in (Figure 4-5). All
immunization groups were intravaginally challenged with 2 x 103 IFU of Chlamydia
muridarum. Genital tracts from each animal were aseptically removed, weighed,
photographed, and grossly assessed for upper genital tract sequelae formation and
severity 35 days post infection. Three female C57BL/6 mice which were not immunized
or challenged were used as a negative reference.
Unlike their non-challenged counterparts (Figure 4-6), all immunization groups
displayed some level of oviduct disease (Figure 4-8). 40% of mock immunized animals
displayed unilateral hydrosalphinx formation while 20% displayed bilateral oviduct
involvement. 20% of animals immunized with C. muridarum or C. muridarum and alum
adjuvant exhibited unilateral oviduct disease. Interestingly, 20% of animals immunized
with alum adjuvant alone displayed bilateral hydrosalpinx while unilateral oviduct
pathology was observed in 40% of the same immunization group.
Uterine horn dilation was seen in all groups immunized (Figure 4-9). 60% of
animals immunized with C. muridarum alone displayed mild dilation with a mean
severity score of approximately 1. Eighty percent of animals immunized with C.
muridarum and alum adjuvant were found to have dilated uterine horns with 60% of
those being mildly dilated and 20% displaying moderate dilation. Only 20% of alum
adjuvant immunized animals displayed uterine involvement, whereas, 60% of mock
immunized animals experienced uterine horn dilation.
Discussion
Although C. trachomatis lower genital tract infections may resolve without
adverse reproductive complications [164] [245] [246], a subset of those infected may
develop upper genital tract sequelae. Presently, Chlamydia control initiatives focus on
identifying and treating individuals before, at least in humans, irreversible tissue damage
occurs. This approach is complicated by the fact that most human chlamydial infections
are often asymptomatic. As a result, the most effective way of controlling chlamydiae
infections would be to develop a vaccine. Although the studies outlined in this Chapter
fail to provide definitive answers pertaining to protection against chlamydial infection,
they do highlight the need for ongoing vaccine development initiatives to consider the
pathogenesis approach given the overarching goal of any Chlamydia trachomatis
vaccination effort would be to preserve reproductive health by preventing the
development of severe disease manifestations.
In the systemic model of chlamydial infection we showed that a detergentextracted preparation of C. psittaci-derived COMC protected mice from lethal
intraperitoneal challenge. To our knowledge, this is the first study of its kind and the
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Figure 4-8.

Oviduct pathology severity of immunized and challenged groups.

Note: Solid bars represent the mean severity score for each immunogen group. Symbols
represent individual animals (N= 5 per group except for normal control).
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Figure 4-9.

Uterine horn pathology severity of immunized and challenged groups.

Note: Solid bar represents the mean for each immunogen group. Symbols represent
individual animals (N = 5 per group except for normal control).
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results inspired us to examine the efficacy of COMC in the C. muridarum urogenital
model given the fact that mice intravaginally infected with Chlamydia muridarum
develop genital sequelae similar to that observed in human populations. Seeing as the
development of genital morbidities such as hydrosalpinx and endometritis are more
subtle than the mortality (survival vs death) end point observed in the systemic model, we
opted to co-administer alum adjuvant in subsequent genital tract experiments as a way of
enhancing the responses observed with homologous COMC antigen. Additionally,
aluminum hydroxide, aluminum phosphate, and aluminum sulfate are the only vaccine
adjuvant formations licensed in the United States and are currently being used in vaccines
directed against the intracellular pathogens, hepatitis B virus (HBV) and human
papilloma virus (HPV) [247].
In our studies, COMC-alum immunized groups (Figure 4-1E), as hypothesized,
fared better than mock immunized groups (Figure 4-1B) and live immunized groups
(Figure 4-1A) displaying no increases in uterine horn or hydrosalpinx formation. As we
hypothesized, DBA/2J mice immunized with live C. muridarum and challenged with C.
muridarum displayed the most severe pathology with both endometrial dilation and
oviduct inflammation (Figure 4-1A). These findings complement our studies and the
studies of others that suggest chlamydial infection recurrence increases the risk for
reproductive sequelae [177] [179] [248].
By far the most interesting observation was the fact that alum adjuvant and PBS
immunized animals displayed no signs of chlamydial-induced pathology or reddening
which is indicative of inflammation. While Th2-driven responses such as those prompted
by the alum adjuvant have been shown to promote immunopathology in chronic diseases
such as schistosomiasis [249] [250], autoimmune diseases, and allergies, more recent
studies have implicated TH2-linked responses to tissue repair and wound healing. As a
result, we hypothesized that a Th2-type response may play a protective role in upper
genital tract disease formation.
To experimentally address the effects of alum adjuvant on chlamydial-induced
genital tract pathology we immunized female C57BL/6J mice with alum adjuvant, alum
and whole organism C. muridarum, or intact C. muridarum organisms alone. Based on
the observations seen in the COMC urogenital studies, we hypothesized that alum only
severity scores would be on par with severity scores associated with non-immunized,
non-challenges animals (negative controls). Interestingly, animals immunized with alum
adjuvant alone displayed severity scores comparable to those observed in alum/C.
muridarum and C. muridarum alone immunization groups (Figure 4-9). While the alum
alone observation was unexpected, we were encouraged by the fact that all immunization
groups exhibited less severe disease, as indicated by mean severity score, than the mockimmunized PBS group which complemented the results seen in the preliminary COMC
urogenital studies (Figure 4-4 and Figure 4-9).
There are at least two, not mutually exclusive, explanations for the discrepant
results seen in the alum adjuvant alone group. One is the mouse inbred strain we used in
the follow-up studies. We substituted the DBA/2J mouse strain originally used in the
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COMC studies for the C57BL/6J inbred strain because B6 animals used in ongoing,
unrelated studies in our laboratory routinely exhibit more severe genital tract disease
when compared to DBA/2J animals. We hypothesized that by using the ‘more severe’
B6 background we would stratify the results seen between groups, making the potential
benefits of alum immunization easier to identify. We know that the enhancement effects
of alum are less pronounced than that of other adjuvants like Freud’s complete adjuvant
(FCA) and are optimal when used in conjunction with an immunogenic compound.
Assuming the upper genital tract sequelae observed in our model is mediated, at least in
part, by the host immune response, it is possible that the B6 TH1-bias was too much for
alum adjuvant to overcome which manifested as mild disease. Secondly, but not less
important, is the chlamydial preparation used in the study. Chlamydiae-derived outer
membrane complex preparations were used as immunogen in the preliminary studies
while whole viable organisms were used in the alum efficacy studies. This is important in
that the alum alone immunized group scores (Figure 4-9) are indistinguishable from
Chlamydia muridarum-alum and Chlamydia muridarum alone group scores. In using
concentrated COMC preparations, we directed the host response against known
immunogenic proteins associated with the chlamydial membrane. Perhaps statistical
differences were not observed amongst immunization groups, including alum alone,
because we diversified the anti-chlamydial antibody pool by using whole organisms over
purified COMC preparations. While it is conceivable that either or both of these
explanations contributed to differences seen in our alum efficacy experiments, further
study is needed to draw definitive conclusions.
While data presented in this Chapter would, seemingly, negate the hypothesis put
forth in Chapter 2 relating to the potential benefits of having TH2-related IL-4 present late
during recurrent infection that is not the case. Our hypothesis hinges on the idea that IL-4
is detectable late during recurrent infection cycles as a way for chlamydial hosts to repair
severe tissue damage. In our studies, alum adjuvant was administered concurrently with
chlamydial immunogen, prior to the development of severe upper genital tract
complications. It is logically to hypothesize that a portion of time in which the host
perceives ‘self-damage’ is necessary for the gearing up of potentially protective TH2related responses. As stated previously, this is only a hypothesis albeit formed from data
derived from ongoing chlamydial genital studies in our laboratory. The continuation and
translational relevance of the studies reported in this Chapter are currently being
investigated in our laboratory and are supported, at least in part, by the recent report
published by Rodolfo et al suggesting an evolutionary genital tract bias for Th2 responses
as a mechanism to prevent chlamydial-induced genital tract complications in humans
[195].
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CHAPTER 5.

CONCLUSIONS

The reproductive health of women is of particular concern with current CDC
Chlamydia surveillance data indicating increases in reported chlamydial infections,
perhaps, in part, as a result of rapid antibiotic intervention. To this end, we interrogated
the murine model for its potential to serve as a translational bridge between populationbased epidemiology and previous animal and human studies. Our studies reaffirm the
benefit of rapid antibiotic intervention in Chlamydia control efforts and suggest an added
benefit during repeated infection even in the absence of antibiotic treatment. Moreover,
our results suggest a TH2-independent role for IL-4 in genital tract tissue repair.
Testing the IL-4 Hypothesis
IL-4 as a mediator of TH2-driven immunity is well established but the role IL-4
may play in genital tract tissue repair is largely unknown. In our studies we show
elevated levels of systemic IL-4 late during recurrent chlamydial genital infection and
cellular infiltrates that are known to produce IL-4 in the genital tract. We also show a
correlation between systemic IL-4 and disease severity. To assess the role of IL-4 in the
arrested immunity model, longitudinal studies are necessary. In these studies we would
measure the onset, duration, and resolution of TH1 and TH2-linked cytokines and disease
progression. This is important given the fact that tissue repair mechanisms rely on the
presence of tissue damage. If IL-4 is indeed a driver of in vivo tissue repair, at least in
this model, it is plausible that the production and secretion of the cytokine would begin
with or after the development of chlamydial-induced pathology. Future studies should
also measure IL-4 transcription levels in implicated cell types (mast cells and
eosinophils) to confirm that they are the primary source of IL-4. These studies would be
followed by IL-4 knockout studies that examine the effect of IL-4 on collateral tissue
damage during multiple rounds of chlamydiae infection.
Identifying Genetic Link to Age-Dependent Disease Severity
Studies are currently underway using B (C57BL/6) x D (DBA/2J) recombinant
inbred mouse strains to identify genetic factors that may modulate disease susceptibility
in an age-dependent manner. By interrogating the GeneNetwork database using a forward
genomic approach, we hope to identify genes associated with the modulation of oviduct
and uterine horn disease severity in an age and strain dependent manner. If disease
severity is associated with specific genetic loci, human cell culture studies focused on
RNA silencing will ensue. These studies will be followed with in vivo studies using
knockout mice specific for the identified gene(s).
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Implications for Vaccine Development
It is generally accepted that an effective anti-chlamydial vaccine would need to
elicit a robust TH1-type CD4+ T cell response but our studies suggest that prophylactic
control of chlamydiae may be more complex than originally appreciated. If the goal is to
clear the pathogen from the site of infection and minimize the likelihood of developing
adverse reproductive upper genital tract complications, eliciting TH1-linked immune
responses may not be enough. It may be beneficial for the host to mount a mixed
immunological response (I.E. TH1/ TH2). Our work highlights the need for additional
studies aimed at addressing the role of mixed cell-mediated responses in chlamydial
infection and immunopathological genital tract damage.
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APPENDIX A.
MORBIDITY AND PATHOLOGY SEVERITY POSTPRIMARY INFECTION IN DEFERRED TREATMENT STUDIES

Note: C57BL/6 female mice were purchased from Jackson Laboratories at 7-8 weeks of
age. Animals were subcutaneously treated with progesterone at days 14 and 7 per
intravaginal challenge. On day 0, animals were intravaginally challenged with 2 x 103
IFU C. muridarum. UN refers to animals that did not receive treatment during the
courseo f the experiment. (0-14) represents animals that were intraperitoneally treated
with doxycycline starting at day 0 for 14 days consecutively. (2-16) represents animals
that were intraperitoneally treated with doxycycline starting 2 days post primary
challenge for 14 days consecutively. (4-18) represents animals that were intraperitoneally
treated with doxycycline starting on day 4 post primary challenge for 14 days
consecutively. Normal represents negative the negative control group which neither
received treatment nor intravaginal Chlamydia muridarum challenge. Animals were
sacrificed 56 post-primary infection.
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APPENDIX B.
MORBIDITY AND PATHOLOGY SEVERITY POSTSECONDARY INFECTION IN DEFERRED TREATMENT STUDIES

Note: C57BL/6 female mice were purchased from Jackson Laboratories at 7-8 weeks of
age. Animals were subcutaneously treated with progesterone at days 14 and 7 per
intravaginal challenge. On day 0, animals were intravaginally challenged with 2 x 103
IFU C. muridarum. UN refers to animals that did not receive treatment during the course
of the experiment. (0-14) represents animals that were intraperitoneally treated with
doxycycline starting at day 0 for 14 days consecutively. (2-16) represents animals that
were intraperitoneally treated with doxycycline starting 2 days post primary challenge for
14 days consecutively. (4-18) represents animals that were intraperitoneally treated with
doxycycline starting on day 4 post primary challenge for 14 days consecutively. Normal
represents negative the negative control group which neither received treatment nor
intravaginal Chlamydia muridarum challenge. Animals were sacrificed 56 postsecondary infection.
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APPENDIX C.
TH1-RELATED CYOKINES POST RECURRENT
INFECTION IN ARRESTED IMMUNITY MODEL
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APPENDIX D.
TH2-RELATED CYTOKINES POST RECURRENT
INFECTION IN ARRESTED IMMUNITY MODEL
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